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SUMMARY
Phenylketonuria (PKU) is an inborn error of amino acid metabolism. It occurs in 
approximately 1 in 10,000 of the United Kingdom population and follows an autosomal recessive 
pattern of inheritance. The disease results from a deficiency or defect of the enzyme 
phenylalanine hydroxylase which converts phenylalanine (phe) to tyrosine (tyr). In PKU there is 
an accumulation of phenylalanine that is toxic to the developing brain and causes mental 
retardation, spasticity and seizures. The treatment of PKU is the adherence to a special phe- 
restricted diet with amino acid, vitamin and mineral supplements. There are guidelines for the 
duration of dietary therapy in the United Kingdom produced by the Medical Research Council 
(MRC) Steering Committee on Phenylketonuria. These guidelines have been reviewed recently 
and lifelong diet is now recommended.
This study began prior to the publication of these recommendations at a time when many 
centres discontinued diet in early adolescence. The rationale for stopping diet in adolescence is 
that the majority of brain development is complete by the end of childhood. The risks to the brain 
of the subsequent rise in phe levels in adolescence and adulthood after diet cessation remain 
unclear. The impetus to this study was the emergence of reports of adults with PKU (who had 
discontinued diet after childhood) developing new neurological signs such as spasticity of the 
limbs. Magnetic resonance imaging (MRI) of the brain in these patients showed an abnormal 
signal in the cerebral white matter and it was initially suggested that the MRI changes depicted 
the structural abnormalities causing the loss of function in these individuals. It was postulated by 
these authors that elevated phe levels in later life had a toxic effect on myelin and that adults 
with PKU were at risk of later onset neurological damage.
This study was designed to obtain more information about brain function in adults with PKU who 
had stopped dietary treatment and to attempt to ascertain whether the MRI abnormalities 
described in several adults had any clinical significance. It was initially designed in 2 stages with 
a period of observation between stage I and II. However, after the MRC PKU guidelines were
xvi
published during the study, the participants were given the opportunity to return to diet. Hence in 
the second stage of the study many patients were on some form of dietary treatment.
The initial study group was aged 14-48 years. They were patients with PKU who had 
discontinued dietary treatment at age 14 years. This group were examined for signs of 
neurological abnormalities, underwent comprehensive neurophysiological testing and MRI of the 
brain. The study was later extended to include MRI of a younger group of patients aged 10-14 
years who were still on diet. This younger group were studied to see whether dietary therapy 
and therefore lower phe levels protected against the development of abnormal brain MR images 
seen in the older group, They did not participate in the neurophysiological investigations.
Clinical examination was normal in the majority of the patients. In 11 of the 58 examined, brisk 
reflexes were illicited. Five of these 11 patients had a fine tremor at rest. Neurophysiological 
testing showed a significant difference between the mean visual evoked potentials latency of the 
PKU group and a control group. There were no other significant differences between the groups 
on neurophysiological testing. Central motor conducting time was marginally prolonged in three 
individuals with PKU, visual evoked potentials in eight and peripheral nerve conduction velocities 
in five.
MRI brain abnormalities were present in 71 of the 74 patients scanned. The changes consisted 
of an increased T-2 weighted signal in the periventricular white matter indicating an increased 
water content of the myelin. A scoring system was used to assess the extent of abnormalities. 
The mildest changes involved only the occipito-parietal areas of the brain whereas more severe 
changes extended into the frontal lobes. The severity of the white matter appearance was 
unrelated to findings on clinical examination or the results of neurophysiological tests. The extent 
of MRI change was most significantly associated with phenylalanine levels around the time of 
MRI scan. There was no significant association between MRI severity and early exposure to 
phe.
X V I I
Fifty-seven patients had repeat MRI scans after an interval ranging from 3 to 12 months. Sixteen 
of these were in the younger group and made no dietary alteration between scans. In the older 
age group who were on a normal diet at the first scan, five patients returned to a strict low-phe 
diet aiming for blood levels less than 400 pmol/l, 21 returned to a low phe diet and restarted 
amino acid supplement aiming for levels around 900 pmol/l and the other 15 made no dietary 
alterations and had blood phe levels around 1200 p mo I/I.
The extent of white matter abnormalities on repeat scanning was again related to the phe level 
at the time of scanning. An improvement in the MRI appearance was recorded in those patients 
who had achieved lower phe levels. The greatest improvement was seen in those who had 
reduced phe levels to < 400 pmol/I. In the group who lowered phe levels slightly to <900 pmol/l, 
four scans showed a marginal improvement. There was little change in the patients who made 
no dietary changes. The extent of MRI improvement was significantly related to the degree of 
reduction in blood phe levels. Two adults underwent serial MRI scans before and after reducing 
phe levels to < 200 p mo I/I. No change in scan appearance was seen after a period of four 
weeks.
Thirty of the adult group aged 14-49 years had repeat neurophysiological testing after one year. 
There were no significant changes in the results recorded from the previous year.
The main conclusions drawn from this work are that MRI white matter changes are a common 
finding in adolescents and young adults with PKU. Clinical or sub-clinical abnormalities are 
however unusual and their presence is unrelated to the changes observed on cerebral MRI. The 
MRI changes form a typical distribution in the periventricular area of the brain and their extent is 
most closely related to blood phe levels at the time of scan. The MRI abnormalities do not 
fluctuate on a daily basis. They are reversible when blood phe levels are reduced but changes 
take more than four weeks to disappear.
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1. INTRODUCTION
1.1 Background
Phenylketonuria (PKU) is one of the most common inherited metabolic diseases in the 
United Kingdom occurring in approximately 1 in 10,000 births (1). In the majority of cases, it is 
due to a deficiency or defect of the enzyme phenylalanine hydroxylase (2,3). Patients with this 
disease are unable to metabolise the essential amino acid phenylalanine (phe) which 
accumulates in the body and is associated with damage to the developing brain. Without specific 
treatment the disease results in severe mental retardation, microcephaly and spasticity (4). 
Neonatal screening has been carried out for this disorder in the United Kingdom since the 1960s 
and children whose elevated phe levels meet certain diagnostic criteria are started on a phe- 
restricted diet (1). This diet includes artificial food products which provide other essential amino 
acids, vitamins and minerals whilst specifically restricting the quantities of phe. The diet is 
successful at preventing the severe complications associated with untreated PKU and is usually 
strictly followed at least throughout childhood (5-7). After childhood it had, until recently, been 
considered safe by many to discontinue or at least relax the diet, as the majority of brain 
development is thought to be complete in the first decade of life.
Recently there have been concerns about the development of neurological abnormalities in 
adults whose phenylalanine-restricted diet has been relaxed or discontinued (8-10). These 
reports added to the body of concerning evidence on the safety of diet cessation in PKU and led 
to the Medical Research Council (MRC) Steering Party on PKU recommending dietary treatment 
to be lifelong (11). This project aims to investigate several features in relation to the 
development of late neurological effects in a group of young adults.
1.2 Definition of the disorder
Hyperphenylalaninaemia is the inclusive term for a group of disorders that result in an elevated 
plasma phenylalanine greater than 120 pmol/l (12). Phenylalanine is an essential amino acid 
making up between 4 and 6% of the amino acid content of natural proteins and plasma 
concentrations are normally maintained within physiological limits by a balance between Inflow 
from ingested protein, endogenous protein turnover and conversion of phenylalanine to tyrosine 
in the liver (13). The hyperphenylalaninaemlas are a heterogeneous group caused by mutations 
at several different gene loci responsible for coding components of the hydroxylation reaction 
(14). They can be divided into phenylalanine hydroxylase (PAH) deficient and non-PAH deficient 
forms. Non-PAH forms result from errors in biopterin metabolism and present a different 
phenotype (13). PAH deficient hyperphenylalaninaemia itself includes a range of phenotypic 
presentations. It can be divided further according to the degree of hyperphenylalaninaemia that 
occurs after ingesting a normal protein diet (15). When the plasma phe is above 1200 pmol/l on 
a normal protein intake, the disease is sometimes referred to as "classical" PKU. It is this group 
of patients that are described in this thesis and the term PKU will be used hereafter for this 
condition.
1.3 Clinical description
In 1934, Dr. Asbjorn Foiling Investigated two mentally retarded siblings, aged six and three years 
old, whose mother had noticed that the children exuded an unpleasant odour (16). Other than 
the mental retardation, there were no positive signs on examination. However, when Foiling 
examined the urine he found that the addition of ferric chloride produced a green colour. The 
substance responsible was identified as phenylpyruvate and Foiling called this disease 
'imbecillitas phenylpyruvlca.' On further studies it was confirmed to be a disorder of 
phenylalanine metabolism (2,3). As a result of screening children in mental institutions more 
patients were identified and the phenotype became recognised to consist of mental retardation 
with spasticity and epilepsy. Affected patients also have a mousy odour, are prone to eczema
and are hypopigmented with blonde hair and blue eyes. The name phenylketonuria was 
introduced by Penrose and Quastel (17) due to the elevated urinary excretion of phenylketones 
that occurs in affected patients. Treatment was first attempted by Bickel in 1953 (18,19) and 
Woolf in 1954 (20). In the initial description of the application of a low phenylalanine diet by 
Bickel (18), a two year old child with PKU who had marked developmental delay showed 
remarkable Improvement in alertness and development within months of starting the diet. In an 
attempt to ensure this improvement was secondary to the diet, the child was fed phenylalanine. 
After the introduction of phe to the diet, the girl began to lose developmental skills again. The 
benefits of dietary treatment were thus established.
It is now realised that the phenotype of PKU is not uniform and that there are some individuals 
who despite not receiving treatment will not develop any of the classical features of the disorder 
(21). These people born prior to the introduction of newborn screening remain undiagnosed 
unless they conceive and produce offspring with the features of phenylalanine toxicity in utero 
such as microcephaly, mental retardation, growth retardation and congenital heart disease (22). 
The identification of such women of childbearing age remains a public health problem. Some 
regions have addressed this issue by adding blood phe testing at booking-in clinics in addition to 
the antenatal screening already established (23).
The major clinical feature resulting from PKU is neurological damage manifest as mental 
retardation, spasticity and epilepsy (4). Despite the increase in knowledge of the biochemistry of 
this condition, much of the neuropathology remains speculative. The current literature relating to 
the neuropathology of PKU is described later.
1.4 Diagnosis and treatment
In order to detect inborn errors of phenylalanine metabolism, routine neonatal screening for PKU 
using whole blood obtained by heel-prick, is carried out in almost all countries with well- 
developed systems of health care (4). In the United Kingdom the chosen upper limit of normal 
varies from 180 to 240 pmol/l and the recommended time for testing is between 6 and 14 days 
after birth (24). Treatment consists of a reduction of natural protein intake to a minimum 
necessary to maintain phenylalanine in the required treatment range. This regime would not 
allow enough protein for growth; therefore a phenylalanine free protein substitute is given in 
sufficient quantities to provide the other amino acids necessary for normal development (25,26). 
Energy intake from carbohydrate and fat must be sufficient to avoid protein catabolism since this 
would lead to an endogenous elevation of blood phe levels. An adequate provision of minerals 
and vitamins must also be ensured (25).
1.5 Biochemistry
PKU results from an error in the phenylalanine hydroxylation pathway. The phe hydroxylation 
reaction is the rate-limiting step in the catabolic pathway that leads to the complete oxidation of 
phenylalanine to carbon dioxide and water (27). The body's supply of tyrosine is produced via 
this pathway and therefore in PKU tyrosine becomes an 'essential' amino acid since it cannot be 
manufactured from phenylalanine (27).
Phenylalanine hydroxylase activity in humans is largely restricted to the liver (27). Although PAH 
is detectable in reasonable amounts in the rat and guinea pig kidney, it is unclear whether it is 
present in appreciable levels in humans (28-32). The hepatic phenylalanine hydroxylating 
system contains three components: PAH, dihydropteridine reductase (DHPR) and the 
unconjugated pterin tetrahydrobiopterin. The reactions catalysed by PAH hydroxylase and 
DHPR in the presence of the pterin are shown in figure 1.
Figure 1: Biochemical pathway of Phenylalanine metabolism
Phenylalanine hydroxylase
Phenylalanine " Tyrosine
tetra hy d ro b io pte ri n quinonoid-dihydrobiopterin
Dihydropteridine reductase
6-py ruvoy Itetrahyd ropteri n
guanosine triphosphate
1.6 Genetics
1.6.1 Phenylalanine hydroxylase gene
PKU is inherited as an autosomal recessive trait. Prior to the widespread use of molecular 
biological techniques, little was known concerning the structure and location of the gene 
encoding phenylalanine hydroxylase in man. In 1982 Robson et al. (33) synthesised cDNA from 
mRNA purified from rat liver by polysome immunoprécipitation. This clone was then used as a 
hybridisation probe to isolate several human PAH cDNA clones from a human liver cDNA library. 
The longest of these clones encoded a protein composed of 452 amino acids, with a predicted 
molecular weight of 51,862 (34). The amino acid composition of human PAH as deduced from 
the nucleotide sequence of the cloned DMA was very similar to that reported for the human 
protein (35). The PAH locus was assigned to chromosome 12 in 1984 (36). This localisation was 
achieved by hybridising human PAH cDNA probes with human/rodent cell hybrids containing 
different combinations of human chromosomes. The locus was localised further to band region 
q22-q24.1 region of chromosome 12 in 1985 (37).
The phenylalanine hydroxylase (PAH) gene is approximately 90 kilobases in length, contains 13 
exons with intron sizes ranging from less than 1 to more than 20 kb, and encodes a mature 
messenger RNA of approximately 2.4 kb (38).
The PAH protein is a homopolymeric enzyme comprised of 52 kDa subunits. Comparisons of the 
primary structures of PAH proteins from different species (39) or of PAH and related 
hydroxylases in mammalian species (40) reveals a high degree of homology in regions of the 
protein encoded by exons 4 to 11 of the human PAH protein, with the highest degree of 
homology in the regions encoded by exons 7 to 9. This central region has been hypothesised to 
be important for the common functions of these proteins, namely binding of oxygen, cofactor and 
the catalytic conversion of substrate, while those features unique to individual proteins, such as
substrate specificity may lie outside this region (27). The importance of this region is reflected in 
the large number of PKU-causing mutations found in this region in many ethnic groups.
1.6.2 Disease causing mutations in the PAH gene
The introduction of PCR-based mutation detection techniques has resulted in a rapid increase in 
knowledge of disease-causing mutations of the PAH gene. Large deletions of the PAH gene are 
not a frequent cause of PKU (27). The majority of other mutations are point mutations including 
nonsense, splicing and missense mutations. Many of the mutations occur in regions of the gene 
that are highly conserved. There are at least 25 missense mutations occurring at sites that are 
conserved in human PAH, rat tyrosine hydroxylase and rabbit tryptophan hydroxylase (40). The 
occurrence of disease-causing mutations at these regions suggests that these areas are 
extremely important for normal enzyme function. Exon 7 has the highest relative frequency of 
mutations associated with PKU but rather than being a particularly mutatable site it is thought 
that this exon confers an essential function for hydroxylation of phenylalanine (41). Using newer 
mutation detection methods It is now possible to characterise 99% of PKU disease causing 
mutations in some populations (42).
These newly developed detection methods will become extremely useful in characterising 
populations. In the English population, like many of the western European populations, the 
majority of individuals with PKU show compound heterozygosity for disease causing mutations 
(43). Unlike some countries where the majority of individuals share the same PKU mutation 
(44,45), there are several disease causing mutations implicated in England. Characterisation of 
the prevalent mutations cannot be performed by targeting techniques to detect specific 
mutations and gene-scanning techniques have to be used (46). Tyfield et al., (43) have used 
heteroduplex detection to identify mutations in the South West area of England and Scotland. 
Guldberg et al., (42) detected 99% of mutations in the Scandinavian population using direct 
gradient gel electrophoresis. Zschoke et al., (47) advocate a stepwise approach to mutation 
detection using a fluorescent multiplex assay for detection of three common mutations followed
by minihaplotype analysis to determine rare mutations which are confirmed by restriction 
enzyme analysis. The third step uses DGGE and sequencing to detect remaining mutations.
The most common mutations cited so far for the English population are R408W, I65T and 
IVS12nt (43). Mutations in the phe hydroxylase gene of the North Western population of England 
have recently been studied (Lesley Heptinstall, personal communication). This community 
shows a similar distribution to the previously quoted figures for England with R408W being the 
most frequently found mutation.
1.7 Efficacy of treatment
The efficacy of early treatment of PKU was shown in a study of 28 sibling pairs in whom one of 
each pair underwent dietary treatment (48). The index cases were late diagnosed children with 
PKU. Their IQ’s were compared with those of an affected sibling who had been diagnosed and 
treated in the newborn period. The average IQ of the late diagnosed group was 45 (range 30 to 
81) whereas in the early diagnosed group the IQ’s were all above 80. A US sibling pair study 
compared IQ’s of an early treated PKU child with their unaffected sibling in 36 sibling pairs (49). 
The PKU group average IQ was 94 and the unaffected group was 99. The North American 
Collaborative Study then undertook to evaluate the outcome of treatment by performing 
intelligence testing at regular intervals (50,51). Mean IQ at 4 years of age in 111 PKU children 
was 93; children treated in the first month had a higher mean score (95) than those treated 
between 31 and 65 days of age (85). This group was followed for several years. At age 8 years 
the PKU group mean IQ of 100 again verified the benefits of treatment. However, comparison 
with siblings showed that the PKU group had an IQ deficit. Furthermore, patients who had 
terminated the diet at an earlier age scored lower that those who had continued it longer (50,51). 
The UK MRC/DHSS PKU Register has followed up patients with PKU diagnosed by newborn 
screening in the UK since 1964. Data from this resource indicates that dietary treatment in PKU 
is successful in avoiding the brain damage seen in the majority of untreated cases. It has 
become apparent however, from the PKU register and other studies that some subtle changes in
intellect exist (52,53): PKU individuals have, on average, IQ’s 0.5 standard deviations lower than 
their sibling’s (54). In addition, several studies have identified other abnormalities in 
neuropsychological performance. Although all these studies differ slightly in the methodology, 
there is sufficient data to suggest that PKU can cause a variety of subtle abnormalities in 
performance. Abnormalities have been identified in simple reaction times (55), sustained 
attention (56), visual spatial motor function (57), perceptual motor function (58) and problem 
solving (59-61). In the UK, according to the PKU Register protocol, a behavioural assessment is 
completed by the schoolteacher at eight years. These assessments have identified 
abnormalities in behaviour in children with PKU consisting of hyperactivity, increased levels of 
anxiety and a tendency to solitude (62).
The overall merit of dietary treatment is widely accepted but the age at which it is safe to 
discontinue diet (If, in fact, it is safe at all) is not clear. There have been several studies aimed at 
assessing the effects on intellect after discontinuing dietary therapy. An early study followed a 
small group of American children for 2 years after the age of diet cessation aged 4 years (63). IQ 
dropped four points during that period. It was considered that this was insufficient evidence for 
diet continuation but that larger and longer scale trials were indicated. A larger trial between 
London, Warsaw and Heidelberg measured neuropsychological performance after termination of 
diet in two centres and relaxation in the third (5). Although IQ fell in all three groups the deficit 
was less in the group in Heidelberg who had not ceased diet completely. These findings were 
not however corroborated by the North American studies of Koff et al., (64) or Koch et al., (7). It 
is thought that differences in interpretation of neuropsychological testing may account for the 
lack of concurrence between these trials (65). In general the results were interpreted by many 
centres that diet cessation was detrimental early in childhood and could result in a fall in IQ 
score.
In the studies described above, the diet was generally terminated in early childhood, but recently 
it has been more common practice to continue diet at least until the age of ten years. There is 
less data available which measures the safety of stopping the diet after childhood. Beasley et al.
(66) report from the UK PKU registry on a group of patients detected by newborn screening 
between 1964 and 1971. It has been previously shown in this group that IQ is closely related to 
early phenylalanine control but that this effect was less pronounced after the age of eight-ten 
years (54). At age 18 years the group were re-tested. Twenty-three percent were on some form 
of relaxed PKU diet. After IQ was taken into account at age 14 years there was no further 
independent effect on IQ from phenylalanine levels after that time. Fisch et al. (67) assessed 19 
early treated PKU patients who had been off diet for 12-28 years. Their IQ had not fallen greatly 
after diet cessation but five of the group had some form of mental illness and the authors 
concluded that IQ alone was not the prime consideration in whether it is safe to cease dietary 
treatment. Ris (68) reports on a group of adults with PKU who underwent a neuropsychological 
assessment aged over 18 years. Ten of the group were still on some form of diet, seven had 
stopped in adolescence and eight had discontinued it at various stages before adolescence. 
Those who had remained on the diet had better intellectual outcome. None of the group had 
overt neurological problems. Some clinics have maintained a diet for life policy (69) for many 
years. However, most centres have, until recently, allowed some relaxation of diet in 
adolescence in the knowledge that most of their patients have already stopped strictly adhering 
to the diet by that age.
1.8 Literature review on neurological problems
Interest in the question of the vulnerability of the adult brain to high phenylalanine levels has 
been renewed recently due to some reports of neurological deterioration in the older PKU 
population and the appearances of the PKU brain on magnetic resonance imaging.
In 1989, Villasana et al. (10) described 2 patients with hyperphenylalaninaemia. One of these 
patients, who had been diagnosed and started diet late at 3 years after investigation for mental 
retardation, developed spasticity aged 28 years. Diet had been discontinued at 12 years. MRI 
showed increased signal intensity around the centrum semi-ovale. Visual evoked potentials 
showed delayed latency as did sural nerve conduction. After re-commencement of a phe-
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restricted diet, nerve conduction velocities returned to normal and clinical examination showed a 
reduction in muscle tone. Spasticity was still apparent and there was no report of a repeat MRI 
scan.
Villasana reported a seoond patient with HPA who was reviewed at 18 years after presenting 
with poor school performance (10). This patient had been diagnosed on newborn screening and 
treated neonataily, but had discontinued dietary treatment when aged 6 years. The only 
neurological abnormality clinically apparent was fine tremor of the outstretched hands. However, 
MRI again demonstrated increased signal in the periventricular area. Neurophysiological testing 
was normal and attempts at re-instituting diet were unsuccessful.
Following this in 1990, Thompson et al. (8) investigated seven PKU patients who had developed 
neurological abnormality. Four of this group had been diagnosed on newborn screening and 
three were diagnosed in childhood after presenting with developmental delay. Of the early 
treated patients, problems such as low IQ, poor growth and behavioural problems had 
developed in late childhood or early adolescence. Three of this group were thought to have good 
early control of diet. However, only one had an IQ above 90. All six patients who underwent MRI 
scanning had abnormal results with high signal areas in the cerebral white matter. Two patients 
with clinical abnormalities were followed serially with scans. One did not alter either on scan or 
clinically. Diet did not change in this two-year period. The other patient improved clinically after 
recommencement of diet. This was associated with a disappearance of some of the 
abnormalities on MRI.
There are difficulties in the interpretation of these findings. The early histories mention poor 
growth and low IQ’s in some of the patients suggesting that the treatment of these patients was 
sub-optimal. Some of the patients whose phe levels were documented In the acceptable range 
even had poor growth and special learning needs. Although these reports were very important in 
that distinct neurological signs were documented in adults who had received some treatment for 
their PKU. it was difficult to know whether the patients formed an atypical group and whether the
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work could predict outcome for teenagers who had maintained good biochemical control and 
were currently clinically normal.
An important feature of Thompson's paper (8) was the apparent reversibility of symptoms and 
MRI abnormalities on returning to diet in one case thus suggesting an effect possibly related to 
transiently elevated levels of phenylalanine.
Reversal of white matter changes was also reported in a single case by Battistini (70). An 18- 
year-old girl with PKU had developed depression and anxiety: neurological examination revealed 
hypotonia and weak abdominal reflexes and MRI of brain showed white matter abnormalities. 
Repeat MRI after two years on a low phe diet showed resolution of white matter changes.
In 1991, Bick (9) studied nine adolescents with PKU. This paper uses the term hyperphe rather 
than PKU and characterises the severity of the disorder according to Guttler's classification, 
which is based on phe levels on a protein intake of 2g/kg (15). In this categorisation, type I 
corresponds to classical PKU, type II to hyperphenylalaninaemia with phe levels > 600 pmol/l 
requiring diet and type III is hyperphe not requiring diet. Two of the group had type ill hyperphe. 
Two boys with Type I (‘classical’ PKU) were late diagnosed at 1.8 years and 2 years and the 
other five children started diet by seven weeks. Two were still on diet aged 17 years at the time 
of study; one had stopped diet at 2.5 years, the others from 8-13 years. The group underwent 
VEPs, IQ and MRI. Clinical examination in the early treated or untreated children was normal. 
The two late treated children had neurological abnormalities consisting of mild spasticity of lower 
limbs and mental retardation. In all the patients with Type 1 or Type 11 hyperphe, marked changes 
in signal intensity in the periventricular white matter were seen on MRI scans. This is the same 
distribution as had been previously been documented. The scan was normal in the Type III 
patients. In the more severely affected patients, the lesions extended to the frontal and 
subcortical white matter. One of these patients who had continued diet from age six weeks and 
whose control was thought to be good also had cerebral atrophy. In addition his IQ was only 87. 
Visual evoked potentials were delayed in five of the eight patients tested; one of who had not
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required treatment and had a normal MRI scan. There was no association between the MRI 
findings and the initiation, duration or quality of treatment or clinical neurological status.
Thompson further investigated this problem by scanning 25 asymptomatic PKU patients aged 7- 
25 years (71,72). Surprisingly, 23 of this group had increased signai intensity on MRI. Most of 
the group had achieved phenylalanine concentrations between 180 and 480 pmoi/i during the 
first 8 years of life and seventeen of the group were still on diet. The subtler scan changes were 
seen in the younger patients who had never been exposed to long-term high phe levels. Patients 
who were known to have measurements of >1200 pmol/l for prolonged periods had the most 
extensive abnormalities. Neurological examination showed only hyperreflexia and tremor in 12 of 
the patients. Statistically significant associations were established between age, phe at time of 
scanning and phe in the period leading up to scan. This is the first paper that suggests a 
correlation between metabolic control and extent of MRI abnormality.
Shaw et al. (73,74) initially identified the white matter changes in a single case and then found a 
similar pattern in ten patients aged 13-27 years. They too recognised that the white matter 
abnormalities were less severe in those with satisfactory dietary control.
Pearsen performed MRI on fifteen patients with PKU (75). An attempt was made to correlate 
MRI scores with IQ and biochemical exposure. There was no positive association with either. It 
was noted that frontal lobe white matter change was present only in those with more severe 
white matter involvement.
Toma scanned 22 patients with PKU and found similar white matter changes in 9 of the group 
(76). Only those with good biochemical control had normal scans. The age range of this group Is 
not reported.
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A group of 16 well-controlled PKU children (6 of who did not warrant treatment) were examined 
in adolescence by Lou et al. (77) with neuropsychological testing, VEP, EEG and MRI. Two 
children had proton spectroscopy.
This is one of only 2 studies reporting proton spectroscopy results to date. Contrary to Ludolph's
(78) and Bick's work (79), VEPs were normal. EEG abnormalities were frequent in the occipital 
lobe. MRI was abnormal only in 2 of the group with Type III hyperphe (not requiring diet). 
However all the others demonstrated some degree of MRI abnormality. Proton spectroscopy of 
an involved patch showed a normal proton spectrum, which indicated that there was no active 
demyeiination at that site. Lou et al. (77) concluded that the abnormalities were more likely to 
relate to early exposure to high phe levels unlike the conclusions of Thompson et al. (72) who 
found that the degree of MRI abnormality related to later exposure to high phenylalanine levels. 
However, the results of proton spectroscopy in Lou et al.'s (77) report have added information by 
indicating that the lesion highlighted on MRI is not likely to be demyeiination at least not in the 
sense of known demyelinating illnesses.
In Walter et al.’s study thirteen young adults with classical PKU underwent MRI (80). The 
number of individuals with abnormal scans is less in this group than in other reports. This is 
possibly due to the younger age range of the participants. Previous phenylalanine exposure was 
assessed in detail but no relationship could be established with present MRI abnormalities. Lack 
of correlation could relate however to the small numbers studied in this report.
Leuzzi et al. (81) investigated 22 early treated and 5 late treated PKU patients. Ten of the early 
treated group were still on diet and the other twelve had discontinued dietary treatment. 
Biochemical control was also assessed in detail in this study and positive correlations were 
found between MRI severity and phe levels in the year prior to scan. In the early treated group a 
significant correlation also existed between MRI severity and median monthly serum phe values 
for the whole period of treatment and for the period from age 4 years until MRI scanning. There 
was no significant association between MRI severity and age at scan, phe control until age 4
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years or age at diet discontinuation. Soft clinical signs were observed in some of the group but 
there did not appear to be a significant association between the presence of clinical 
abnormalities and MRI scores. This paper was important in suggesting that MRI changes were 
related more to recent phe levels than early control although the number of patients studied in 
each group was small.
The most recent published work to emerge during the period of my study and is that of Bick et al.
(79). In this report 10 adolescents and adults with PKU were investigated with MRI of brain, 
proton spectroscopy, T2 relaxometry and VEPs. This work adds support to the theory that the 
lesions seen on MRI are not indicative of active demyeiination. Additionally T2 relaxometry 
suggests that the abnormalities represent free water in the myelin. There was no consistent 
relationship between MRI changes and IQ, time at diagnosis or initiation of therapy or VEP 
changes. MRI changes tended to be more severe in those with poor dietary control and high 
current phe levels. Reversal of changes was observed in 2 patients after strict diet was initiated. 
Bick concluded that the observed white matter changes probably represent reversible structural 
myelin changes rather than permanent demyeiination.
The various clinical reports available are conflicting. Neurophysiological work has found normal 
and abnormal VEPs, EEGs, and NCVs. Neuropsychological tests have consistently documented 
PKU children to perform less well than their normal counterparts.
There is clear evidence that MRI changes exist in some young adults with PKU (8-10,70-73,75- 
77,79-81). The reports concur in the type of abnormal MRI signal produced in PKU and in the 
anatomical areas involved. The cause, duration and functional significance are not clear. There 
is a suggestion that levels of phe are important but It is unknown whether this relates to phe at 
time of scan or in the preceding lifetime. Reversibility has been noted in five patients (8,70,79).
The work to date highlights a problem; that adults with PKU, even those well treated from the 
neonatal period are at risk of developing abnormalities on MRI brain scans. A smaller number
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may be at risk of developing florid neurological abnormalities. Studies to date have been on 
small numbers. The criteria for case selection are unclear in many of the studies and the 
population base is uniformly unstated. The following questions emerge from a review of the 
literature.
1) What is the nature of the abnormalities on MRI imaging or neurophysiological studies?
2) How long has it been there?
3) Is it progressive?
4) Is it clinically important?
5) Is it reversible with dietary manipulation?
6) Is it related to biochemical control of PKU?
7) is there any relationship between MRI scan abnormality and other indicators of neurological 
status such as neurophysiological measurement?
8) Is the development of neurological abnormality related to specific genetic mutations?
1.9 Neuropathology of PKU
In order to plan a study of the possible neurological complications of PKU it is necessary to 
review the aetiology of the brain damage occurring in PKU and attempt to relate this to the 
normal process of myelination. Despite the expansion in knowledge of PKU, the mechanism of 
brain damage resulting from the disorder remains unknown. Although a certain amount of 
information is available on the effects of PKU through post mortem studies on humans which 
show the brain to be underweight and hypomyeiinated (82-85) and dynamic studies on the rat 
model for PKU (86-89), there is no single process that seems to explain the brain abnormalities 
and it is surmised to be multifactorial (90).
Studies on animals are a major source of published data on the metabolic and chemical 
changes in brain associated with hyperphenylalaninaemia. Animals are rendered 
hyperphenylalaninaemic by phenylalanine infusions. However in animals the normal PAH activity
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allows an elevation in tyrosine also. This activity has to be inhibited by infusing agents such as 
p-chlorophenylalanine and alpha-methylphenylalanine. These have their own secondary effects 
including inhibition of other amino acid hydroxylations and are therefore not ideal models (88). In 
1990 however, an animal model, which is genetically manipulated to be PAH deficient, has been 
successfully produced. This mouse shows the phenotypic features similar to the untreated 
phenotype in man and in time will be of value in further animal experiments in PKU (91-93).
The possible causes of the brain pathology can be divided into three main theories:
1) Effect of phe on transport of amino acids,
2) Effect of phe on the synthesis of myelin and
3) Effects of phe on neurotransmitter availability
1) The appearances of the brain in PKU have been likened to that seen in malnutrition and it is 
thought that high phe levels, by inhibiting entry of other amino acids creates a state of protein 
deficiency in the PKU brain (94). Tyrosine is rendered an essential amino acid in PKU since it 
cannot be produced from the hydroxylation of phenylalanine and so it is hypothesised that a 
tyrosine deficient state exists which may jeopardise normal brain development. In Bessman’s 
‘justification hypothesis’ it is speculated that the homozygous PKU fetus is at risk of tyrosine 
deprivation for two reasons (95). Firstly, it is dependent upon the maternal metabolism, which in 
the heterozygote state cannot regulate tyrosine delivery to the fetus as effectively as the 
homozygous normal mother. Secondly, the PKU fetus cannot produce tyrosine itself due to 
inactivity of phe hydroxylation. This theory is unsupported however, by Scriver who 
demonstrated normal tyrosine in the cord blood of PKU infants (96). In addition, tyrosine 
supplementation without phe reduction in PKU does not prevent mental retardation whereas phe 
restriction by itself largely protects brain development (97). Untreated patients may show low 
levels of tyrosine but this is usually in conjunction with deficiencies of other amino acids and a 
more likely explanation for this is the competitive inhibition theory.
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Phenylalanine crosses plasma membranes as it moves in and out of cells and organs. High 
intracellular levels of phe may interfere with the exit of other amino acids from the cell and 
parenchymal tissues contain high levels of amino acids in untreated PKU whereas plasma levels 
are low. In the brain however, the transport relationships are different and an excess of phe 
blocks the influx of amino acids. The brain is therefore deprived of its amino acid supply (94). 
Evidence of a competitive transport system exists between phe and tyrosine, tryptophan, valine, 
leucine and isoleucine and rat models have shown a reduction of these amino acids in the brain 
in the presence of high phe.
2) The exact nature of the insult on myelin resulting in structural changes visible at the 
microscopic level is not clear. Post-mortem examinations of the brain of PKU individuals shows 
reduced brain weight, increased water content and hypomyelination (82-85). Animal models of 
PKU have demonstrated several abnormalities related to myelin. There is evidence of a delay in 
initial myelination, an increased turnover rate of myelin early in life and of disturbed protein 
synthesis (86,87,98). In Prensky's work concentrating on specific myelin components a 
decrease in myelin basic protein, proteolipid protein, cholesterol and galactocerebrosides was 
found (99).
There are no reports of post-mortem findings in individuals with PKU who commenced treatment 
in the newborn period, in whom one would expect a more normal pattern of myelination. In an 
attempt to recreate this situation, rats rendered hyperphenylalaninaemic at 17 days of age were 
studied. This age corresponds to approximately 6-8 years in human beings. The rats were found 
to have an increased turnover of the fast component of myelin and a reduced amount of myelin 
protein (88). This work highlights the vulnerability of the brain to the toxic effects of phe beyond 
the childhood years. This instability of myelin may be due to the underlying effect of phe on ATP- 
sulphurylase (90,100). This enzyme is responsible for sulphate activation and may have a 
regulatory role in the uptake of sulphates by the brain. Elevated levels of phe inhibit this enzyme. 
The regional distribution of phe-sensitive ATP-sulphurylase in fetal calf brain correlates with the 
demyelinated areas of the central nervous system in untreated PKU patients (100). A decreased
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content of sulphatides in the PKU brain has been demonstrated. It is thought that cerebroside 
sulphatides offer a protection against degradation and the relative lack of sulphatides due to 
reduced activity of ATP-sulphurylase may result in the increased tendency to degradation and 
rapid turnover of myelin seen in PKU models.
3) Several studies have focussed on the effects of elevated phe on neurotransmitter metabolism. 
Serotonin and catecholamine biosynthesis is inhibited by elevated phe. However, these effects 
seem reversible when phe levels are reduced (101). Taylor et al. (89) found a deficiency of 
serotonin in the brains of rats rendered hyperphe after the majority of brain development is 
complete thus implying a lifelong vulnerability of the brain to the effects of phe on 
neurotransmitters. Many studies contribute to the evidence that brain dopamine and serotonin 
levels are reduced in PKU (102-105). It is unlikely that such deficiencies cause the mental 
retardation observed in the untreated state. They may be the pathological correlate of 
neuropsychological and behavioural disturbances such as delayed reaction times or poor 
executive functioning but be unrelated to the structural abnormalities described in post-mortem 
reports (83,84).
An elevated phe level may exert different effects on the brain depending on the stage of brain 
development. It is thought that the infantile brain is at greater risk when exposed to a high phe 
than the brain of an older child in whom myelination is complete. Interruption of myelin synthesis 
may lead to severe cerebral difficulties whereas the brain of an adolescent may be relatively 
resistant to elevated phe. Because of this it was felt that relaxation of the diet in PKU was safe in 
adolescents and adults who were finding the constraints of a restricted diet difficult. However it is 
possible that that problems of neurotransmitter synthesis continue to be a problem at all ages 
and therefore that diet discontinuation may not be entirely without hazard.
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1.10 Myelin
The process of myelination is briefly reviewed as an introduction to the consideration of the 
effects of elevated phenylalanine on myelin.
White matter is composed of myelin and non-myelin elements. Myelin makes up most of the 
substance of the white matter of the central nervous system (CNS), about 50-60% dry weight 
and this component accounts for the characteristic white appearance (106). Other elements of 
white matter are the neuroglia consisting of astrocytes, microglia and oligodendrocytes. Myelin is 
also present in large quantities in the peripheral nervous system (PNS). In both the CNS and the 
PNS myelin is essential for the normal functioning of the nerve fibres (107).
Myelin is produced from oligodendrocytes in the CNS (and from Schwann cells in the PNS). The 
oligodendrocyte cell becomes wrapped around the axon many times. As the wrapping occurs, 
the cytoplasm of the sheath cell retracts or is extruded so that the two layers of the sheath cells 
plasma membrane come together and fuse. As a result myelin develops a lamellar structure and 
this can be visualised using electron microscopy and X-ray diffraction (108). Each 
oligodendrocyte is connected to up to 30-60 axons and each axon may have a sheath containing 
around 160 compacted lamellae (106).
Myelin is a membranous structure composed predominantly of lipids and proteins. In addition to 
the lipid-protein core, myelin also contains carbohydrates. The lipids of myelin are composed of 
25-28% cholesterol, 27-30% galactolipid and 40-45% phospholipid (106). Thus the molar 
concentration of cholesterol is greater than that of any other single myelin lipid. The most 
distinguishing feature of myelin lipid is the high content of galactolipids, especially cerebroside 
(107). These lipids are amphipathic. In an aqueous environment, the amphipathic nature of the 
lipids means that a molecular bilayer is formed in which the hydrophobic regions of the lipid are 
turned to the inside and thus shielded from water while the hydrophilic regions are turned to the 
outside and are immersed in ‘water. This lipid bilayer allows interaction with the amphipathic 
proteins, which form an integral part of the membrane. Additional proteins are present on the
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outside of the bilayer. Thus myelin membranes are bilayer structures coated with proteins on 
both sides and the basic repeating subunit is protein-lipid-protein-lipid-protein (106).
In comparison to other molecular bilayers, the myelin bilayer is unique in having a very high lipid 
content (containing 70% to 80% lipids by dry weight) and in containing chiefly saturated fatty 
acids with an exceptionally long chain length (108). This fatty acid composition also adds to a 
highly stable membrane structure.
The protein content of 20%-30% is relatively low (compared for example with liver cell 
membranes which are 60% protein) (107). The major proteins of myelin are proteolipid protein 
(PLP) and myelin basic protein (MBP). PLP is a transmembrane protein and makes up the 
largest component of myelin proteins. MBP is present mainly on the cytoplasmic, surface of the 
myelin bilayer. Together these proteins are thought to be important for myelin stability and 
ordered compaction (106).
The process of myelination is a highly controlled phenomenon evolving with regular times and 
sequences. The initiating stimulus for the onset of myelination remains obscure although the 
axonal diameter is implicated and the presence of neuronal conduction along the nerve is also 
thought to be Important. It is hypothesised that a chemical messenger secreted by neurons 
plays a role or that control is exerted by properties of the axonal membrane (109).
Myelination of the CNS takes place at different times in early development. Not only the rates of 
myelination appear to differ among tracts, but also there is a marked time change in topographic 
patterns of myelination throughout the last half of gestation and during the first postnatal years 
(110). During the last half of gestation and the first two postnatal years, the developing brain 
contains a series of ordered sequences of myelination, some starting early or late in gestation 
and rapidly attaining the maximal degree of myelination, others only slowly attaining the maximal 
degree of myelination (111).
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Myelination in the nervous system is initiated in a caudocranial time sequence, following the 
order of phylogenetic development (110). In general the palaeotologically older structures are 
myelinated earlier than the newer structures and there is some evidence to suggest that the 
tracts in the nervous system become myelinated at the time they become functional (112). At 
birth, most of the structures and tracts are not fully myelinated. Large parts of the cerebral 
hemispheres still contain no myelin. The regions still completely or largely unmyelinated at birth 
are particularly those involved in higher level associative functions and sensory discrimination. 
After birth, myelination progresses but does not reach completion until adult life (113). During the 
first postnatal year myelin spreads throughout the entire brain, Progressively finer branching of 
the subcorticai white matter continues until adult life. Post-mortem studies in which myelin is 
stained and then quantified have showed that in certain areas of the brain such as the 
hippocampus, myelination continues well into adulthood (113).
The introduction of MRI scanning has given more information on the timing of myelination in the 
normal subject (110,112). MRI studies show a rapid myelination in the first two to three years of 
life followed by slow progression until 20-30 years of age (111,114-116), It is thought that fibres 
in the areas around the lateral ventricles are amongst the slowest to myelinate. These areas are 
called the association areas of the brain and continue to myelinate throughout the first several 
decades of life (117).
After formation the myelin sheath and the axon remain mutually dependent (118). Since myelin 
once deposited is metabolically a relatively stable substance, it is relatively invulnerable to 
adverse external factors. The stability of myelin is not clearly understood. Sulphatide and 
gaiactocerebroside (GalC) are thought to play an important role in myelin stability. Supportive 
evidence for this theory arises from the study of genetically manipulated mice designed to be 
deficient in the enzymes responsible for synthesis of sulphatide and GalC (119). In these mice, 
myelin of normal ultrastructural appearance but thinner sheaths is formed and the myelin is rich 
in glucocerebroside instead of GalC. However, the neurological function of the mice is abnormal 
and they develop ataxia, and tremor. Conduction deficits consistent with abnormal myelin are
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observed. The conclusion from this work is that GalC and its sulphated derivative, sulphatide is 
important for myelin stability and function.
Generalised vulnerability of myelin to noxious agents is likely to be confined to the period of 
active myelination since at this time, the large supply of precursors of myelin constituents 
necessary for myelin deposition can be quite readily restricted during their transport into the 
brain. It is reasonable to accept that stress factors will vary in their effect on myelin according to 
the process of myelination. The timing of the stress and its severity will also determine the 
characteristics of and the extent to which myelination can catch up once favourable 
circumstances have returned. The period in which the human infant is most vulnerable with 
regard to myelination probably lasts from about the seventh intrauterine month to the first few 
months or the first year of postnatal life. This theory is borne out by the effects seen in late 
treated PKU, where severe mental retardation is observed when dietary intervention Is delayed 
beyond the first year of life.
In adults there is a continued synthesis of myelin and a slow turnover. Different components 
have different half-lives. There is conflicting data about the precise half-life of the various myelin 
lipids and proteins. Some components do turn over faster than others and all components show 
a slow and a fast turning over component. The data suggest that newly formed myelin is 
catabolized faster than old myelin (120).
Remyelination in the CNS is possible but usually incomplete. It often follows the pattern of 
myelination during development. As a general rule however, remyelination is only extensive 
when the lesion is small. Large areas of demyeiination show remyelination at the margins only. 
Remyelinated fibres have thinner sheaths than normal (121).
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1.11 Investigative techniques planned in the study
1.11.1 Introduction
Although the aetiology of the neurological problems recently described in PKU is unknown the 
MRI findings suggest a problem with myelin (8,9,79). To further investigate the neurological 
status of a group of patients with PKU it is important to perform tests that give information on the 
function and structure of the nervous system. The following sections discuss the background to 
the investigative tools that will be used in this study and describes their previous use in PKU.
Neurophysiological measurements may be a sensitive method of detecting sub-clinical 
abnormalities as they are known to be useful in other demyelinating disorders (122,123).
Electrophysiological studies of the nervous system may be considered an extension of the 
clinical examination. Neurophysiological studies can supplement the examination by providing 
precision, detail and objectivity and delineate a variety of pathological changes that are clinically 
obscure or undetectable. Neurophysiological techniques used in this study are described below.
1.11.2 Nerve conduction studies
Conduction velocity of motor fibres was popularised for study in humans by Modes et al. (124) 
who recorded the mechanical response of a muscle. With improvement of recording apparatus, 
nerve conduction studies have become a simple and reliable test of peripheral nerve function. 
The method has become adequately standardised and is widely used as a means of objectively 
detecting an abnormality in nerve conduction.
The validity of the nerve conduction velocity calculation depends upon the accuracy in 
determining the latencies and the conduction distance. Sources of error in measuring latencies 
include unstable or incorrect triggering of the sweep; poorly defined take-off of the evoked 
response and inappropriate stimulus strength and inaccurate calibration (125,126). Errors in
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measurement of the conduction distance by surface measurement result from uncertainty as to 
the exact site of stimulation and the exact course of the nerve trunk. Surface determination of 
the nerve length may be particularly imprecise when the nerve takes a non-linear path.
Because of these uncontrollable variables, the calculated velocities are not absolute values of 
nerve conduction (127). On repeated testing the values may vary as much as 10 m/s, because 
of the limitations inherent in the techniques. If standard procedures are adhered to however, the 
results are sufficiently reproducible. Since the range of normal is small, the use of nerve 
conduction studies as a clinical diagnostic test is justified. A number of factors such as 
temperature and age can alter motor and sensory conduction studies (127-129) and testing 
conditions must be controlled in the neurophysiology laboratory as well as collecting an age- 
appropriate control group. Adult values of nerve conduction are reached by age three to five 
years and remain in the same range until the fifth or sixth decade (127,129).
1.11.3 Magnetic stimulation of brain
Magnetic stimulation is a relatively new technique for stimulating nerve and cerebral cortex and 
is used to help quantify the characteristics of the nervous system, especially to measure 
conduction times. Its purpose is to create a pulsed electric current that will momentarily 
depolarise the nervous system. Magnetic stimulation of the cortex was first reported by 
d'Arsonval in 1896 (130) but commercial stimulators only became available in 1986. The 
advantage conferred by this new technique is that it provides the ability to introduce currents in 
previously inaccessible areas of the body. A changing magnetic field produced by the magnet 
induces an electrical field in the area tested. This causes electrical stimulation of the nerves in 
that area which produces recordable responses (130).
The first clinical results obtained with the stimulator were reported by Barker et ai. in 1985 (131) 
who showed that there was a marked increase in conduction time in motor fibres between head 
and neck and head and lumbar region in patients with multiple sclerosis. These results were
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subsequently confirmed by others (132-134). Barker also demonstrated a relationship between 
the degree of delayed conduction and the extent of clinical spasticity in patients with MS (131). 
Slowed conduction has since been recorded in other disorders such as cervical spondylosis 
(135). Jarratt et al. have reported a comparative study on visual evoked potentials and magnetic 
stimulation in the diagnosis of MS and conclude that the two investigations together increase the 
diagnostic accuracy in this condition (136).
As a neurophysiological tool, magnetic stimulation seems to be less sensitive at detecting sub- 
clinical lesions in the motor tract in MS than are VEP or SEP at detecting lesions in their tracts 
(137). Nevertheless abnormal responses to magnetic stimulation do correlate with the degree of 
neurological abnormality even if this is merely abnormal reflexes. Theoretically the application of 
magnetic stimulation is an important adjunct to the neurological investigation in PKU for two 
reasons; firstly it has proven benefit in detecting disorders of myelination and secondly it focuses 
the CNS investigation on the motor system which is the area of the nervous system affected in 
all the recent reports of neurological deterioration in young adults with PKU (8-10). it is therefore 
important to be able to assess motor function in detail.
1.11.4 Visual evoked potentials
Pattern reversal visual evoked potentials (VEPs) are a well-established technique for measuring 
nerve conduction along the visual nerve pathway (138). The technique records the cortical 
electric waveform using scalp electrodes produced in response to a rapidly alternating visual 
stimulus of a checkerboard pattern (139,140). The recorded waveform has been shown to be 
consistent between individuals (141). Several reproducible waves are identifiable. The most 
consistent is the major positive component (PI 00) and this is the measurement most often used 
for comparison between individuals. Abnormalities may occur both In the latency of the wave 
and the amplitude. It is generally thought that demyeiination results mainly in a prolongation of 
the latency but can also affect the amplitude (142). This technique is useful In detection of
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demyeiination in multiple sclerosis (122). It is a robust technique if used carefully and control 
values established and is widely used in the diagnosis of neurological disease.
1.11.5 Somatosensory evoked potentials
A somatosensory evoked potential is a cortical or sub-cortical response recorded as a result of 
stimulating a peripheral nerve. The most widely used method of averaging responses was 
described in 1954 by Dawson (143). Using somatosensory testing it is possible to estimate the 
central sensory conducting time (CSCT). Following stimulation of a peripheral nerve a 
reproducible waveform is observed. There are several recording sites available. By placing 
cervical recording electrodes and scalp electrodes the latency of the evoked potential is 
monitored at several sites along the pathway. The CSCT is estimated by subtracting the total 
latency at the scalp electrode from the cervical latency. Again SEPs have found widespread use 
in the investigation of disorders of myelin and are abnormal in approximately 60 % of individuals 
with multiple sclerosis (123). In order to achieve consistency certain precautions have to be 
taken in the laboratory: tests must be performed with the limb temperature above 34 degrees 
centigrade and laboratory age controls should be established.
1.11.6 Neurophysiological studies previously reported In PKU
Since it is a relatively new technique, magnetic stimulation has only been previously reported in 
one previous PKU study by Ludolph et al. (78). Twenty-two adolescents with PKU underwent 
several neurophysiological investigations including magnetic stimulation of cortex. Although 
individual results were normal, the individuals with PKU had a prolonged mean central 
conduction time compared to a group of age matched controls.
There are several reports of the application of other more established neurophysiological 
techniques in PKU.
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An early study by Schafer (144) showed that VEP latency could be shortened by decreasing 
blood phe or supplementing patients with L-Dopa or tyrosine thereby increasing indole and 
catecholamine precursors. Creel et al. in 1982 (145) detected abnormal VEPs in a small group 
of untreated PKU adults.
Pueschel et al. (146) studied 8 children with classical PKU aged 4-6 years through a period of 
diet cessation, measuring VEP, SEP and BAEP while on and off diet. There was no alteration in 
the early component of the waveforms of VEP, SEP or BAEP. The variation in the late 
component was inconclusive: although some patients had a prolongation of the late component 
of the SEP, in some, this developed prior to stopping diet and improved afterwards whereas in 
others the abnormality was detected after stopping diet.
Korinthenberg et al. (147) have studied the largest group to date. EEG, VEP and BAEP were 
carried out in 41 adolescents with PKU. Four had not required dietary treatment. The latency of 
the P I00 peak of the VEP was prolonged in the patients with PKU types I or II who had been 
treated early. The latency was however normal in those with mild PKU and in those with type I or 
II who had been treated late which makes the interpretation difficult. There was a positive 
correlation between quality of treatment in the first 10 years and duration of VEP latency.
Ludolph et al. (78) in addition to using magnetic stimulation, investigated their group of 22 
adolescents with NOV, VEP and SEP. They found subclinical neurophysiological abnormalities 
of statistical significance in the PKU group when compared with age-matched controls. There 
was no obvious clinical significance to these abnormalities. They were unable to correlate the 
findings with previous metabolic control. Indeed visual evoked potential latencies were more 
delayed in the mildest PKU group who had not required treatment and were normal in the more 
severe group. On the basis of their findings they hypothesised a 'morphological and 
pharmacological' basis to the late neurological problems implying that the elevated levels of phe 
cause disruption of neurotransmitters (pharmacological) and that there are also structural 
abnormalities (morphological) of myelin present.
28
Landi et al. (148) examined 14 PKU patients with EEG and VEP. They found abnormalities in 
VEP latency in six children with PKU and EEG abnormalities in three children. There was no 
correlation between the mean phe levels and the neurophysiological results.
The most recent studies reported are those of Bick et al., (79) and Jones et al., (149). Bick’s 
study of eight children formed part of a MRI brain study. Four of the eight children tested had an 
abnormally prolonged VEP. In Jones’s report, the 32 patients’ MRI scan findings had been 
published separately. There were 27 patients aged 14-31 years and over 80% had an 
abnormality of VEP. Of the nine younger patients still on diet only one had an abnormal VEP. 
There were no differences between phe or tyr levels and VEP latency.
There are several studies of EEG changes in PKU. All suggest that there are frequently 
abnormalities in the EEG waveform in children with PKU, (56,77,78,145-147,150-153). 
Epileptiform activity is however, unusual in the treated PKU individual. Krause (153) reports that 
the abnormalities in EEG waveform are influenced by concurrent blood phe levels.
in this study we have used a neurophysiological assessment consisting of
1) magnetic stimulation of the cortex
2) somatosensory evoked potentials
3) peripheral nerve conduction velocities and
4) visual evoked potentials
The rationale for using these specific techniques is firstly to perform a comprehensive 
examination of the nervous system which looks for evidence of peripheral and central 
myelination abnormality, secondly to choose neurophysiological tests that focus on areas of the 
nervous system that are considered to be vulnerable in PKU and thirdly, to exploit knowledge of 
the advantages of neurophysiological techniques in other demyelinating disorders by using 
established techniques which are sensitive at detecting abnormal function of the myelin. Whilst
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considering all these issues the examination had to be of a duration that we could reasonably 
expect patients to attend in addition to their clinic and MRI visits. The duration of the assessment 
was approximately 2 hours.
1.11.7 Magnetic Resonance Imaging
The introduction of MRI scanning to clinical practice has yielded new information on the brain 
appearance of young adults with PKU and suggests that they display abnormal MRI images {8- 
10,70-73,75-77,79-81).
MRI has been used extensively in medicine, especially to investigate disorders of the nervous 
system (154-157). The clarity of Images of the nervous system far outweighs that previously 
given by Computed Axial Tomography (CT) scanning (157). MRI has also been used to evaluate 
brain maturation in infants, children and adolescents (158-160). The diagnostic supremacy of 
MRI in neurological disorders is shown in multiple sclerosis where demyelinated plaques are 
clearly highlighted. In multiple sclerosis, MRI may detect lesions that are not clinically manifest 
nor have any subclinical effect that can be discerned by neurophysiological studies (161-164). It 
has been observed previously that a limitation of MRI may be its high sensitivity coupled with its 
lack of specificity. In serial studies several patients subsequently developed clinical deficit 
concomitant with the anatomical lesion first identified on MRI (163,164), The ability of MRI to 
herald neurological abnormality raises important issues in PKU. MRI abnormalities may develop 
clinical correlation in time or may have no clinical significance. In other disorders however such 
as multiple sclerosis a detailed neurophysiological examination usually highlights some 
dysfunction when MRI shows widespread abnormalities. Therefore in this study when MRI 
abnormalities are severe, it would be reasonable to expect concomitant neurophysiological 
abnormalities if there is permanent structural damage as a result of PKU.
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1.12 Aims of study
This study aims to address some of the questions that arise from a review of the current 
literature. Specifically the null hypotheses to be tested are that:
1) adolescents and young adults with PKU do not have an increased incidence of overt clinical, 
neuroradiological or neurophysiological abnormalities
2) changes on MRI of the brain are not associated with any other marker of neurological disease
3) there is no association between the development of neurological abnormalities and the 
degree of dietary control in childhood
4) MR! changes are not associated with current levels of phenylalanine
5) neurological dysfunction is not progressive over the period of this study
6) MRI changes are not reversible with dietary manipulation
1.13 Design of the study
The study was a prospective examination and follow-up of a large group of adolescents and 
young adults with PKU. In stage I the neurological function of a group of patients who had 
discontinued dietary treatment was established by clinical examination and detailed 
neurophysiological testing. This group also had MRI of brain and the relationship between brain 
white matter abnormalities; neurological status and biochemical control was measured 
statistically. The MRI white matter changes were graded using a scoring system, which allowed 
statistical analysis of the results, A younger group of patients with PKU were also recruited to 
have MRI of brain alone. These patients were still on diet and they were studied when it became 
clear that all the adults had MRI brain changes in order to see whether the abnormalities 
developed even in younger patients on diet.
In stage II, patients made a decision to return to a diet or remain off diet and the examination, 
neurophysiological studies and MRI scans were repeated. The results of stage II were compared
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statistically with those of stage I. The second stage of the study was performed after 
approximately one year.
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2. METHODOLOGY
2.1 Patients
The study population was adolescents and adults with PKU who attended the Willink 
Biochemical Genetics Unit based at the Royal Manchester Children’s Hospital, Manchester. The 
age at diagnosis, diagnostic phe levels and current age of the study population is given in Table 
1.
Patients aged over 14 years who had discontinued dietary therapy were invited to attend for
1) clinical neurological examination,
2) neurophysiological assessment
3) MRI of brain
4) blood phe level
Patients aged 10-14 years were invited to attend for MRI of brain and blood phe only. After a 
period of observation, which ranged from six to twelve months, clinical examination, 
neurophysiological assessment and MRI of brain were repeated in the 14 years and over age 
group and MRI alone was repeated in the 10-14 year olds.
Invitations with tear-off slips were sent to 99 adolescents and adults who regularly attended the 
clinic. Patients who were pregnant were not considered appropriate for this study. If no response 
was received, a second slip was sent. No further action was taken if a negative reply was 
received or if there was no response to two slips,
The Ethics Committees of Salford and Central Manchester Health Authorities gave ethical 
approval.
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Table 1: Details of PKU patients participating in study, their age at start of study, age at 
which treatment commenced, diagnostic phe level and age at diet discontinuation
number age
(years)
age treatment 
commenced 
(days )
diag phe 
(pmol/l)
diet
discontinued
(years)
1 16 12 1280 14
2 17 19 4394 14
3 35 240 NK 4
4 30 14 >1200 5
5 14 14 1748 14
6 18 14 4029 14
7 15 15 NK 14
8 19 17 4120 14
9 14 17 3000 14
10 13 14 NK CONT
11 15 14 3410 14
12 21 17 3600 14
13 18 11 1200 14
14 15 16 3240 14
15 22 16 >1200 14
16 15 20 3760 14
17 13 10 3260 CONT
18 10 15 >1200 CONT
19 26 60 1340 19
20 24 90 2500 14
21 23 16 >1200 14
22 10 15 1402 CONT
23 22 4 YEARS 2489 15
24 23 17 4411 16
25 21 15 3000 11
26 22 20 1200 16
27 21 22 4960 11
28 23 60 1411 17
29 19 8 2328 13
30 25 20 >1200 14
31 12 31 4190 CONT
32 13 10 2590 CONT
33 13 15 2400 CONT
NK; not known
CONT; diet continuing
preg: treated only in pregnancy
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number age
(years)
age treatment 
commenced 
(days )
diag phe 
(jumol/i)
diet 1
discontinued
(years)
34 12 13 1200 CONT
35 24 12 1568 6
36 23 17 >1200 16
37 18 15 3300 14
38 29 14 2100 9
39 13 16 2260 CONT
40 19 17 3255 14
41 13 16 4580 CONT
42 20 11 1200 14
43 17 10 3500 14
44 21 14 1200 14
45 30 3 months 1302 14
46 26 6 weeks >1200 14
47 13 14 2910 CONT
48 10 17 1200 CONT
49 22 26 1800 4
50 48 preg 1647 ---
51 20 6 1200 14
52 31 preg 1200 ----
53 14 15 1500 14
54 17 2 years 1500 14
55 16 25 1322 14
56 19 10 2500 14
57 19 18 2812 14
58 30 5 months 1320 16
59 20 15 1200 14
60 21 23 1958 14
61 23 36 2400 14
62 20 10 2914 14
63 24 11 weeks 1650 14
64 13 21 4590 CONT
65 25 32 3900 14
66 18 15 1200 14
67 16 11 3476 14
68 10 13 2065 CONT
69 10 15 2150 CONT
70 10 14 2370 CONT
71 11 15 2093 CONT
72 13 19 3300 CONT
73 17 22 4308 14
74 25 8 weeks 2605 14
75 21 25 2400 14
76 17 15 5503 14
77 10 19 1830 CONT
78 16 15 3500 10
NK: not known
CONT: diet continuing
preg: treated only in pregnancy
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2.2 Clinical examination
The assessment of the nervous system consisted of a clinical history and the following 
examination:
i) inspection of posture, observation for muscle wasting or fasciculation, voluntary and 
involuntary movements such as tremor
ii) examination of muscle tone
ill) assessment of power in the limbs using isotonic method of testing, 
iv) tendon reflexes assessed as normal, brisk or very brisk,
iv) testing of co-ordination using finger-nose test and rapidly reversing palm-dorsum movements 
of hand test,
The methods used were that of McLeod's Clinical Examination (165).
These examinations were performed at the time of neurophysiological testing with the patients 
semi-recumbent on a testing couch in the neurophysiology department or in the consulting room 
of the clinic.
2.3 Intelligence Quotients
It has been shown previously that the intelligence quotients of the United Kingdom population 
have increased over the years since the population norms were established (166). To counteract 
this effect when looking at IQ results from a group tested in different years. Smith et al. (167) 
suggest converting IQ results to IQ standard deviation scores (IQ sds) and this technique is 
used in this thesis.
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2.3 Neurophysiological tests
2.3.1 Magnetic stimulation of cortex and cervical spine
Magnetic stimulation of cortex and cervical spinal cord was performed using a Dantec S C I20 
magnet (Dantec*) of maximum output 1.4 Tesla. Fifty-five subjects were tested in a semi- 
recumbent position using the technique described by Ingram et al. (133). The resulting action 
potential to cortical and cervical magnetic stimulation was recorded using Ag/Ag 01 electrodes 
affixed to the skin overlying the tendon and belly of abductor pollicis brevis (APB). Stimulator 
strength was increased to a level where the maximum action potential was observed. In the 
majority of cases this was around 70-75 % of maximum output. Readings were taken with a 
reasonable voluntary contraction of APB. Four reproducible latencies were recorded and the 
shortest latency was used for further analysis. Amplitudes were noted from the recordings. A 
group of 45 healthy volunteers (age range 17 to 34 years) was similarly tested. Central motor 
conducting time (CMCT) was derived using 2 methods: from the latency difference between 
cortically-stimulated and cervically-stimulated action potentials and from the latency difference 
between the cortically-stimulated action potential and the peripheral latency as measured by the 
F wave technique (168). The shortest latency of 8 F waves was measured following electrical 
stimulation at the wrist. The peripheral component of the cortically derived conduction time is 
then calculated as F+(M-1)/2 and this value is subtracted from the latency of the response 
evoked by magnetic stimulation of the cortex.
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2.3.2 Peripheral nerve conduction velocities
56 patients had peripheral motor nerve conduction velocities measured for the median nerve by 
recording over APB following stimulation at the wrist and elbow and for the common peroneal 
nerve by recording over extensor digitorum brevis following stimulation at the ankle and at the 
fibular head. Index to wrist median and antidromic sural sensory potentials were also recorded 
by averaging responses. Surface electrodes were used for recording and stimulation and 
supramaximal stimuli were used. A Counterpoint electromyography machine (Dantec*) was used 
in all recordings and 20 healthy volunteers (age range 19 to 40 years) were similarly tested to 
provide control data.
2.3.3 Visual evoked potentials (VEPs)
Pattern-reversal stimulation was performed in 48 patients by 2/s black and white checkerboard 
pattern reversal. The total field subtended 15 degrees at the eye, each square subtending 72 
minutes. Each eye was stimulated separately on whole-field stimulation and patients were asked 
to fixate on the centre of the screen. With a sweep time of 256 ms, 100 sweeps were averaged 
by a Concerto Brain Mapper (Dantec*). The process was repeated to ensure reproducibility of 
the responses. Recording was by a horizontal occipital chain of three Ag/Ag Cl electrodes 
(referred to Fz) at 5 cm intervals, with the central electrode on the midline 2 cm above the inion. 
Readings were made of PI 00 latencies and amplitude was assessed as the peak to peak 
amplitude of P75 to PI 00. Control data were recorded from 20 volunteers age range 18 to 40 
years.
2.3.4 Somatosensory evoked potentials (SEPs)
SEPs were recorded using Ag/Ag Cl disc electrodes over the ipsilateral Erb's point, C7 and C2 
spinous processes and over the contralateral sensory cortex (03 and C4 using the international 
10-20 system) following 2/s median nerve stimulation at the wrist. The stimulus intensity was
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sufficient to produce a reasonable twitch in the APB. 256 responses were averaged using a 
Concerto Brain Mapper (Dantec*) and the recordings were repeated to ensure reproducibility. 
Peaks N9, N11, N13 and N20 latency and amplitude were measured. Central sensory 
conducting time (CSCT) was derived by subtracting N13 from N20 latency. Forty-eight 
individuals with PKU were tested. Control data was available from 25 healthy adults (age range 
18-42 years).
2.4 Magnetic Resonance Imaging
Magnetic Resonance Imaging of the head was performed with patients awake at the Department 
of Radiology at Manchester Royal Infirmary. MRI of the head was performed using a 0.5 Tesla 
(GE) MR system, obtaining sagittal T-| weighted spin echo and transverse intermediate and T2 
weighted sequences through the brain, with a section thickness of 5 mm. Diazepam sedation 
was available if patients felt claustrophobic.
The scans were graded according to severity and extent of white matter changes (see Table 2). 
A score of zero represented a normal scan. The highest possible score for each anatomical area 
was 5 bilaterally and there were 6 anatomical areas scored thus giving a total possible score of 
60. The scans were scored by a single observer (JPRJ), a consultant neuroradiologist who was 
aware that the patients had PKU but not of their clinical or biochemical data.
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Table 2: MRI grading system.
Grade Scan appearance
0 Normal
1 < 10% white matter involved
2 10-30% white matter involved
3 30-50% white matter involved
4 50-75% white matter involved
5 ■ > 75 % white matter involved
Scores of 0-5 are given for each of the following anatomical regions: frontal, parietal, occipital, 
temporal, brainstem and other areas. A score of 0 represents a normal scan; a score of 60 is the 
most severely affected possible.
2.5 Phenylalanine measurement
Blood phe was measured by amino acid analyser (Waters HPLC system using a lithium cation 
exchange column, Pickering Lab Inc, California) or thin layer chromatography. All serial blood 
phe concentrations, from diagnosis until the date of MRI, as obtained for routine monitoring, 
were entered onto computer for each patient. Data were analysed to give the average yearly phe 
concentration (area under the phe curve as plotted against time, divided by the age at MRI) and 
the aggregated times that the blood phe concentration remained below a) 120 pmol/l, above b) 
400 pmol/l, above c) 800 pmol/l and d) above 1200 pmol/l. Early control was assessed from the 
average yearly phe concentration in the first 4 years of life and more recent control from the 
average yearly phe concentration over the five years prior to imaging (80).
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2.6 Control data
Controls were tested for the neurological techniques of magnetic stimulation, peripheral nerve 
conduction velocities, visual evoked potentials and sensory evoked potentials.
There were no control subjects for MRI scans, as normal age-related data were considered 
sufficient.
Healthy volunteers were recruited from doctors, medical students, nurses and technicians 
working in Royal Manchester Children's Hospital or Hope Hospital. Recruitment was by inviting 
colleagues or asking student groups. Nursing staff at Hope Hospital were recruited by a general 
invitation to the wards in close proximity to the Department of Neurophysiology. The only 
exclusion criteria used were epilepsy, pregnancy, presence of a metal implant for magnetic 
stimulation and trauma to the limbs being tested for nerve conduction studies. There was no 
financial incentive for participating.
2.7 Statistical analysis
All variables were tested for normality using the Shapiro-Wilk test. 95% confidence intervals 
were calculated for the difference in the means obtained between the PKU group and a control 
group for each neurophysiological test and for the difference in mean MRI grades for the 
younger and older patients. Individual results were designated as abnormal if the result was 
greater than 2.5 standard deviations outside the mean of the control group. On repeat 
neurophysiological testing the Student paired 'f  test was used to discern changes over time in 
an individual’s results.
The association between MRI severity and phenylalanine control and neurophysiological result 
was assessed using Pearson’s correlation. Stepwise multiple regression was used to further 
investigate these relationships.
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3. RESULTS
3.1 Introduction
The results of the two stages of the study are presented followed by the comparison between 
the findings at each stage.
3.2 Stage I: Initial assessments of PKU group
3.2.1 Clinical examination
Clinical neurological examination was performed in 58 PKU patients of age 14 to 49 years. Of 
this group 11 individuals had abnormal neurological signs. Six patients had brisk tendon reflexes 
alone and five had a tremor at rest and brisk tendon reflexes. No patients had an abnormal gait 
or spasticity of the limbs. The median age of this neurologically abnormal group was 19.4 years 
compared with 20.0 years for the normal group. There were no significant differences between 
the two groups in factors relating to biochemical exposure to phe as shown in Table 3, Median 
MRI grades were similar between the groups, clinically abnormal group median score 12.5, 
normal group 12, p = 0.9.
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Table 3: Comparison of age, biochemical control and MRI score of PKU patients with
normal and abnormal clinical examination
Clinically normal 
n=47
age (years) 
exp (pmol/l/year) 
time<120 pmol/l (years) 
time>1200 pmol/l (years) 
phemax (pmol/l) 
first 4 years(pmol/l) 
last 5 years(pmol/l) 
phe at time of scan (pmol/l)
MRI score 
all values given are median values 
exp: average lifetime exposure to phe
time <120 pmol/l: duration of time that blood phe was below 120 pmol/l
time >1200 pmol/l: duration of time that blood phe was above 1200 pmol/l
phe max: maximum recorded blood phe
first 4 years: average blood phe over the first 4 years of life
last 5 years: average blood phe over 5 years leading up to start of study
p value: probability value
20
779
0.4
2.7
2914
1693
1102
1350
12
Clinically abnormal 
n=11
19.4 
864 
0.6 
5.3 
3500 
1734 
1304 
1500
12.5
p value
0?9........
0.3
0.9
0,2
0.6
0.4
0.4
0.9
0,5
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3.2.2 Intelligence quotients
IQs were normally distributed with a mean of 97 and standard deviation of 17 {figure 2). IQ-SDS 
ranged from -4.6 to 1.77 with a mean of -0.7. There was no correlation between IQ-SDS and 
MRI grades (r=  -0.62, p = 0.3).
Figure 2: Frequency distribution of PKU patients IQ’s
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3.2.3 Neurophysiological testing
The results of all neurophysiological tests are tabulated with patient age, IQ and clinical 
examination result in Table 4.
Table 4: Results of 58 PKU patients aged 14-49 years (discontinued diet at time of 
testing): age, clinical examination, IQ and neurophysiological testing measurements
patient age
(years)
din
exam
IQ cmct
(ms)
vep
(ms)
csct
(ms)
med
mot
(m/s)
med
sen
(m/s)
lat
pop
(m/s)
sural
(m/s)
1 16 N 111 6.2 101 4.5 55 46 50 42
2 17 N 109 7.1 109 5.5 51 50 52 42
3 35 N 87 6.8 NT NT 60 70 NT NT
4 30 N NT 9.5 102 4.8 56 43 57 37
5 14 N 85 6.9 113 4.5 57 46 50 45
6 18 N 98 7.1 NT NT 56 44 NT NT
7 15 N 127 4 108 6 54 42 48 50
8 19 ABN 109 7.6 102 4.9 55 46 66 51
9 14 N 105 5.5 102 6 70 58 48 48
11 15 N 93 6.4 109 5.6 59 45 50 46
12 21 N 80 7.0 104 4.7 53 UT 44 43
13 18 N 113 7.5 111 5.3 45 43 54 58
14 15 N 82 6.8 88 5.4 52 51 49 48
15 22 N 70 8.2 94 5.6 68 55 62 52
16 15 N 111 5.1 98 4.0 61 45 52 38
19 26 N 94 5.2 105 5.6 62 48 57 60
20 24 ABN 83 UT 106 UT 61 45 50 45
21 23 ABN 92 5.1 144 4.7 59 53 41 45
24 23 ABN 117 9.3 109 5.3 62 52 53 43
25 21 N 94 10.8 100 5.2 59 41 50 44
26 22 N 106 5.5 NT NT 63 37 48 53
27 21 N 87 5.6 NT NT 66 50 46 33
28 23 ABN 90 7.3 110 3.5 55 42 42 43
29 19 N 107 7.0 109 5.5 58 48 54 46
36 23 ABN 94 5.1 99 5.2 74 53 65 46
N: normal clinical examination
ABN: abnormal neurological examination
NT: not tested
UT: uninterpretable trace
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Table 4 continued
patient age
(years)
din
exam
IQ cmct
(ms)
vep
(ms)
csct
(ms)
med
mot
(m/s)
med
sen
(m/s)
lat
pop
(m/s)
sural
(m/s)
37 18 N 102 7.1 108 4.9 68 55 63 45
38 29 ABN 100 8.3 94 5.1 65 48 52 38
40 19 N 97 8.2 109 6.1 35 UT 42 47
42 20 N 101 6.5 102 6.0 53 42 46 63
43 17 ABN 72 7.0 110 6.7 58 60 46 44
44 21 N 106 UT 104 5.2 60 38 44 38
45 30 N 69 5.4 100 4.7 64 46 54 53
46 26 ABN 90 6.3 107 4.9 65 51 48 47
49 22 N 33 NT 104 NT NT NT NT NT
50 48 N 61 5.6 102 4.7 58 50 55 50
51 20 N 77 5.8 123 4.7 65 55 50 42
52 30 N 105 6.3 105 5.8 63 43 51 47
53 14 N 96 7.0 111 5.6 70 54 58 50
55 16 N 92 4.0 104 5.5 61 46 48 64
56 19 N 106 6.8 94 5.5 58 54 46 UT
57 19 N 105 8.2 NT NT 55 55 51 43
58 30 N 71 5.5 107 5.2 60 55 40 47
59 20 N 105 5.7 106 3.9 58 48 42 42
60 21 N 121 6.9 NT NT 61 50 57 45
61 23 N 125 7.1 103 5.0 57 50 46 UT
62 20 N 138 5.7 NT 5.0 58 41 46 43
63 24 ABN 128 7.2 104 6.0 53 50 UT 36
65 25 N 110 6.1 102 5.6 60 55 50 42
66 18 N 122 6.8 99 5.3 61 45 50 47
67 16 N 91 9.6 108 4.3 59 48 48 41
73 17 N 119 7.8 107 5.3 52 35 54 34
74 25 N 94 7.1 102 4.2 62 52 50 43
75 21 ABN 89 6.8 98 5.5 59 52 53 41
76 17 N 6.9 5.8 97 60 46 52 UT 53
23 22 N 100 6.2 NT NT 62 50 48 52
54 23 N 84 NT NT NT 59 51 49 51
78 16 N 90 NT NT NT NT NT NT NT
30 17 N 110 NT NT NT NT NT NT NT
N: normal clinical examination
ABN; abnormal neurological examination
NT: not tested
UT: uninterpretable trace
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3.2.3.1 Magnetic stimulation of the cortex
Results are reported from both recording techniques for determining an estimation of CMCT.
F wave method CMCT
Using the F wave method, the mean latency of the central motor conducting time was 6.8 ms 
(95% Cl: 6.42 to 7.18) for the PKU group and 6.6 ms (95% Cl: 6.24 to 6.96) for the control 
group. This difference did not reach statistical significance (Cl for difference in means -0.32 to 
0.72). Individually, there were 3 patients whose CMCT lay outside the upper limit of normal 
(mean + 2.5 s.d.= 9.6, PKU values 9.8, 10.2 and 10.3 ms). These patients’ details are given in 
table 5. A scatter diagram of the results is in Figure 3.
Cervical magnetic stimulation method CMCT
Following cervical magnetic stimulation, the mean CMCT latency was 6.9 ms (6.50 to 7.30) for 
the PKU group and 6,7 ms (6.34 to 7.06) for controls. This difference is not statistically 
significant (Cl for difference in means -0.36 to 0.76). The same individuals had CMCT outside 
the normal limits.
Table 5: PKU patients with abnormal CMCT results
Patient age (years) years off diet current phe (pmol/l)
24 23 6 1650
25 21 6 1000
67 16 5 1000
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Figure 3: Scatter diagram of central motor conducting times in PKU group and controls
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3.2.3.2 Visual Evoked Potentials
The mean latency of the major positive P100 peak of the VEP was 105.3 ms (Cl 102.7 to 107.8) 
in the PKU group, and 100.5 ms (Cl 98.4 to 102.5) in the controls, which was significantly 
different (95% Cl 1.6-8.0). There were 8 individuals whose latencies were above the upper limit 
of normal (mean + 2.5 s.d.= 111.6 ms). Two were markedly delayed at 133 ms and 123 ms 
whereas the others ranged from 112-114 ms. The details of these individuals are given in table 
6. Mean amplitude for the PKU group was 10 milliV (s.d.7) and 15 milliV (s.d.5) for the control 
group. This difference was not statistically significant. Cl for difference in means: -0.68 to 10.6. 
Figure 4 is a scatter diagram of the results.
Table 6: PKU patients with abnormal VEP results
Patient age (years) years off diet current phe (pmol/l)
2 17 3 1350
5 14 0.5 1200
21 23 9 1730
43 17 3 1700
46 26 12 1880
51 20 7 700
53 16 2 1200
74 25 11 1700
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Figure 4: Scatter diagram of visual evoked potentials results for PKU group and controls
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3.2.3.3 Somatosensory evoked potentials
Reproducible waveforms were recorded in 46 of 48 individuals tested. Central sensory 
conducting time (CSCT) was not statistically different from controls, CSCT PKU = 5.2 ms (Cl 5.0 
to 5.4), controls = 5.3 ms (Cl 4.9 to 5.7), Cl for difference in means: -0.57 to 0.30. There were no 
individual abnormally prolonged results.
3.2.3 4 Peripheral nerve conduction velocities
Median nerve motor and sensory nerve conduction velocities were similar to controls. Mean 
median nerve motor conduction velocity was 59 m/s (57.2 to 60.9) in the PKU group and 60 m/s 
(58.4 to 62.0) for controls. Cl for difference -3.7 to 1.33). One patient recorded a median nerve 
conduction velocity of 45 m/s which was outside the lower limit of normal (mean - 2.5 s.d = 50 
m/s. Median nerve sensory conduction velocity was 49 m/s (46.8 to 50.4) in the PKU group and 
50 m/s (47.7 to 52.4) for controls, Cl for difference -4.44 to 1.4. One abnormal value (lower limit 
of normal 37m/s) was recorded in the PKU group of 35 m/s. In the lower limbs, common 
peroneal motor conduction velocity was 50.5 m/s (48.7 to 52.2) in the PKU group and 51.5 m/s 
(48.0 to 55.0) for controls, Cl for difference -4.85 to 2.8. There were no individuals with results 
outside the normal range. Mean sural conduction velocity was 46 m/s (43.9 to 47.8) in PKU and 
46m/s (44.4 to 48.4) in controls. Cl for difference -3.35 to 2.17. individually there were 4 
abnormal results of sural nerve conduction velocity in the PKU group (mean - 2.5 s.d.=35.4 m/s) 
and details are in Table 7. These values ranged from 27 m/s to 35 m/s. Figure 5 is a scatter 
diagram of the results for median nerve motor conduction velocity.
51
Table 7: PKU patients with abnormal NCV results
patient abnormal NCV age (years) years off diet current phe 
(pmol/l)
13 median nerve motor 18 4 1500
73 median nerve sensory/ 
sural nerve
17 3 1300
2 sural nerve 16 2 1000
27 sural nerve 21 10 1800
67 sural nerve 16 2 1000
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Figure 5: Scatter diagram of results of median nerve motor conduction velocities in PKU
group and controls
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3.3 Magnetic resonance imaging
Three individuals did not tolerate scanning due to claustrophobia. Only one child had a normal 
scan and two others had equivocal scans. The other 71 scans showed some degree of 
abnormality. This consisted of an increased intensity of the MR signal on the T2 weighted image 
in the white matter. The areas affected most commonly were the posterior occipito-parietai lobes 
(affected in all patients with abnormal scans) and the frontal lobes (involved in 90% of affected 
scans). Occasional patients had temporal lobe or basal ganglia abnormalities. Examples of the 
images obtained are shown in figures 6-8. In the majority of patients the abnormal signal was 
uniform throughout the affected areas but in 16 patients there were also discrete punctate 
lesions of stronger signal in certain areas. The scores ranged from 0 to 25, with a mean and 
median of 12. There was a significant difference in the mean MRI score between the younger 
group still on diet and the older patients, mean score 10-14 years = 9 (Cl 7.2 to 10.8), mean 
score 14+ years = 12 (01 10.9 to 13.1), 95% 01 for difference in means 2.48 to 3.52. Figure 9 is 
a frequency distribution of the MRI grades.
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Figure 6: Photograph of T-2 weighted MRI of head showing a normal scan
t
\
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Figure 7: Photograph of T-2 weighted MRI of head showing cerebral white matter 
abnormalities scored 12.
The arrow highlights the abnormal white matter.
À\
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Figure 8: Photograph of T-2 weighted MRI of head showing cerebral white matter 
abnormalities scored 25.
The arrows highlight the abnormal white matter.
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Figure 9: Frequency distribution of MRI grades in 71 PKU patients
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3.4 Relationship of MRI with age and IQ of PKU patients
The results of Pearson’s correlation between MRI grade and age and IQ are shown in Table
Table 8: Correlation between MRI grade and age and IQ
r P
Age at MRI scan 0.24 0.08
IQ -0.62 0.28
r: correlation coefficient, p: probability value
3.5 Relationship of MRI with neurophysiological abnormalities
The results of Pearson's correlation between MRI grade and neurophysiological results are 
shown in Table 9. There was no significant correlation between MRI grading and any of the 
neurophysiological findings. The plots of these relationships are in Appendices 1-7.
Table 9: Correlation between MRI grading and neurophysiological investigations
Neurophysiological test r P
Central motor conducting time (CMCT) 0.03 0.78
Visual evoked potentials (VEPs) 0.04 0.86
Central sensory conducting time (CSCT) -0.23 0.16
Sural nerve conduction velocity (NCV) -0.08 0.6
r: correlation coefficient, p; probability value
59
3.6 Relationship of MRI with biochemical control
Correlation analysis of MRI grade and biochemical control is shown in Table 10. There was a 
significant correlation (p<0.05) between MRI abnormality and average life phe exposure, phe in 
the last 5 years and phe at time of scanning. There was no association between MRI grade and 
time phe >1200 pmol/l, time phe <120 pmol/l, first 4 years exposure to phe or maximum phe. 
The strongest correlation was between severity of scan abnormalities and phe at the time of 
scanning. Stepwise multiple regression analysis showed phe at the time of scan to be the 
strongest association. When this variable was accounted for, no other factor showed a 
significant association. The least squares linear regression equation for this association was MRI 
grade=0.00514 x phe level + 5.67. The plots for the significant associations are shown in Figures 
10-12. The other plots are in Appendices 8-11.
Table 10: Correlation of MRI grade and biochemical control
r P
Time blood phe <120 pmol/l -0.21 0.13
Time blood phe >1200 pmol/l 0.26 0.06
Mean blood phe throughout life 0.38 0.0043 *
Mean blood phe in first 4 years 0.16 0.27
Mean blood phe in last 5 years 0.40 0.0025 *
Maximum blood phe 0.21 0.12
Blood phe at time of MRI scan 0.58 0.0002 *
r: correlation coefficient, p: probability value 
* denotes the statistically significant results
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Figure 10: Plot of MRI grade and blood phe at time of scan
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Figure 11: Plot of MRI grade and average exposure to phe
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Figure 12: Plot of MRi grade and average blood phe in the five years leading up to scan
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3.7 Stage II results
3.7.1 Introduction
In this section, the results of repeat clinical examination, neurophysiological tests and MRI scans 
in the second stage of the study are presented. The results of stage I were explained to the 
patients. At this time the Medical Research Council published guidelines for the treatment of 
PKU including a recommendation for diet for life (11). On this basis the patient study group 
made a decision regarding their diet. There was no attempt to randomise the patients.
3.7.2 Details of patients dietary status in stage II
Forty-one of the original 58 patients on a relaxed diet were re-scanned. Of this group, five 
patients decided to return to a strict phe restricted diet, re-starting amino acid supplement and 
aiming to reduce the phe level to 400 pmol/l. Twenty-one patients wanted to restrict the phe 
intake to a certain degree and restart supplement but felt they could not achieve levels as low as 
400 pmol/l. This group aimed for levels around 900 pmol/l. The remaining patients (totalling 15) 
did not wish to make any alteration to diet and their levels remained around 1200-1500 pmoi/l. 
The younger patients did not make any dietary alteration between first and second scans; they 
maintained a phe restricted diet and amino acid supplement aiming for blood phe levels <700 p 
mol/l. Tables 11-13 show the different groups of patients studied in the second stage of the 
project.
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Table 11: Patients on strict diet In second stage of project: ages, phe levels and time
interval between scans
patient age at first 
scan (years)
phe at stage 1 
(pmol/l)
phe at stage II 
(pmol/l)
ôphe ôtime
(months)
6 18 1200 500 -700 6
5 15 1500 100 -1400 3
9 14 1200 900 -300 6
19 26 1350 400 -950 12
74 25 1700 300 -1400 4
Ôphe: change in blood phe levels between stage I and stage II of the study at time of repeat MRI 
scanning
Stime: time interval between first and second stage investigations
65
Table 12: Patients on low protein diet in second stage of project: ages, phe levels and
time interval between scans
patient age
(years)
phe at stage 1 
(pmol/l)
phe at stage II 
(p mo I/I)
ôphe Ôtime
(months)
1 16 1000 700 -300 6
2 17 1350 1200 -150 6
5 14 1200 500 -700 8
14 15 1500 800 -700 12
13 18 1500 1350 -150 12
15 15 1500 1000 -500 6
23 22 1500 1300 -200 9
24 23 1650 1500 -150 6
25 21 1800 900 -900 12
36 23 1650 1200 -450 12
28 23 1500 900 -600 6
37 18 1800 1500 -300 14
42 20 900 900 0 12
46 26 1700 1200 -500 9
44 21 1000 600 -400 13
45 30 1000 800 -200 13
55 16 1300 900 -400 6
59 20 1200 750 -450 10
66 18 1500 800 -700 9
67 16 1000 750 -250 8
73 16 700 700 0 7
ôphe: change in blood phe levels between stages I and II of study 
ôtime: time interval between stages I and II of the study
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Table 13: Patients who made no dietary alteration between stages I and II: ages, phe
levels and time interval between scans
patient age
(years)
phe at stage 1 
(pmol/l)
phe at stage II I 
(pmol/l)
ôphe (pmol/l) ôtime 1 
(months)
8 19 1500 1500 0 12
12 21 1200 1200 0 13
20 24 1350 1500 150 6
26 22 1350 900 -450 6
38 29 1400 1200 -200 7
40 19 1200 1200 0 7
50 48 1500 1000 -500 12
51 20 700 750 50 12
53 14 1200 1500 300 12
56 19 1500 1500 0 12
57 19 1500 900 -600 6
60 21 300 600 300 6
61 23 1700 1500 -200 14
62 20 1500 900 -600 9
65 25 1500 1500 0 12
Sphe: change in blood phe levels between stages I and II of study 
Ôtime: time interval between stages I and II of the study
3.7.3 Results of repeat clinical examination
30 patients returned for repeat neurophysiological testing. On repeat testing those patients with 
abnormal signs exhibited similar signs. Two patients previously considered to be normal were 
noted to have brisk reflexes. These were patient 40 aged 19 years and patient 37 aged 18 
years.
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3.8 Results of repeat neurophysiology
3.8.1 Magnetic stimulation of cortex
Repeat tests were performed on 30 patients. This group which was retested were a similar 
group to those who declined retesting in terms of age and biochemical severity. There was no 
difference in CMCT between stage I and stage II of the study. Only the F-wave method is 
reported. The results are given in Tables 14 and 15.
Table 14: CMCT results of 30 PKU patients re-tested in stage II of study
Mean CMCT (ms) Confidence Interval
6.3 5.7-6.8
F wave method n=30
Table 15: Comparison of CMCT’s between stages I and II of study in PKU patients
Mean CMCT stage 1 6.5
Mean CMCT stage II 6.3
Confidence interval for difference in means -0.68 to 0.25
n=27
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3.8.2 Visual evoked potentials
Repeat tests were performed in 30 patients. The difference between the groups fell just outside 
the 95% confidence limits, the mean latency of the group studied in stage II being slightly shorter 
than in the initial study. When this difference was examined more closely the improvements had 
occurred in the group who had returned to a strict diet. The results are shown in Tables 16 and 
17.
Table 16: VEP results of 30 PKU patients re-tested in stage II of study
Mean VEP (ms) Confidence Interval (ms)
104 101 to 107
Table 17: Comparison of VEPs between stages I and II in PKU patients
Mean VEP stage 1 (ms) 105
Mean VEP stage II (ms) 104
Cl for difference in means (ms) -0.02 to 3.94
n=27
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3.8.3 Peripheral nerve conduction velocities
Repeat nerve conduction velocities were performed in 30 individuals. There were no significant 
changes in results between first and second testing. The results are given in Table 18 and 19.
Table 18: NCV results of 30 PKU patients re-tested in stage II of study
Nerve tested mean NCV (m/s) Confidence interval of mean
Median nerve motor 59.0 56.8 to 61.2
Median nerve sensory 51.3 48.1 to 54.7
Lateral popliteal nerve 52.0 48.8 to 55.1
Sural nerve 
................................
44.4 40.7 to 48.1
Table 19: Comparison of NCVs between stages I and II of study in PKU patients
Nerve tested Cl for difference in means
Median motor nerve -2.0 to 2.8
Median sensory nerve -7.6 to 1.1
Lateral popliteal nerve -7.0 to 2.3
Sural nerve -2.3 to 8.6
n=30
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3.9 Results of repeat MRI scanning
41 patients attended for repeat scanning from the 58 older patients who had been on a relaxed 
diet at the time of first MRI scan. Two of the group were pregnant at the time of second scan, the 
remaining 15 did not wish to be rescanned. Seventeen of the 19 patients aged 10-14 years were 
rescanned. They had made no dietary alteration during the year.
Of the group of 41 patients, 5 patients returned to a strict phenylalanine (phe) restricted diet with 
amino acid supplement (Maxamum Scientific Hospital Supplies Ltd, Liverpool) reducing plasma 
phe levels to < 400 pmol/l. Twenty-one patients reduced protein intake and recommenced amino 
acid supplement, aiming to reduce plasma phe levels to < 900 pmol/l. The remaining 15 patients 
made no dietary alteration. Mean plasma phe of this group was 1200, range 900 to 1500 pmol/l. 
Tables 11-13 shown previously give the patient details in each group.
The results on repeat scanning of the younger and older groups are analysed separately. Table 
20 shows the mean grades before and after dietary changes in each sub-group. A graph 
depicting the grades at first and second scans is shown in figure 13. All scans improved in the 
group who had returned to a strict diet (mean change in MRI grade: -5, range -4 to -6). In the 
group who had reduced protein intake and commenced amino acid supplement, six scans 
improved, nine remained the same and two worsened slightly. In the group who made no dietary 
alteration, most scans were unaltered. Two patients’ scans improved, in these patients the phe 
level was in fact lower at the time of second scan.
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Table 20; MRI grades at first and second scans in each dietary group
MRI grade at 
1 st scan
MRI grade at 2nd 
scan
ÔMRI
strict diet n=5 13 (10 to 17) 9 (5 to 13) -4 (-6 to-2)
low protein diet n=21 13 (11 to 15) 13(11 to 15) 0 (-1 to 0)
no change n=15 12(9 to 15) 12 (9 to 15) 0 (-1 to+1)
MRI grades are mean grades for the group with confidence intervals given in parenthesis 
ôMRI: represents the change in MRI grade between first and second scans
The association between the change in plasma phe levels between scans and the change in 
MRI score is shown in Figure 14. There was a highly significant association between the change 
in MRI grade and the change in the plasma phe level (Pearson's correlation: r = 0.57, 
p = <0.001). The least squares regression equation for this association was MRI grade = 0.003 
phe + 0,32.
The association between the change in MRi scan and phe levels at second scan is shown in 
Figure 15. The association is significant. It can also be seen from this plot that scan 
improvement was nearly always in those whose phe levels were below 900 pmol/l. Figure 16 
shows MRI scans on a patient whose scan improved three months after reducing phe levels 
from 1200 pmol/l to 300 pmol/l.
For the younger group of patients aged 10-14 years, repeat scanning was performed after a 
period of one year during which no changes were made to their diet. The MRI scores were not 
significantly changed over the period of observation (mean ôMRI 0) nor was there a significant 
alteration in blood phe levels (SPFIE 70). The plot of the association between 5MRI and ôphe is 
shown in Appendix 12.
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Figure 13: Depicts the MRI grades In stages I and II of the study In each different dietary 
group
MRI grade MRI grades in stages I and II
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3.10 Relationship between MRI scanning and neurophysiology
As in the first stage of the study there was no statistical relationship between MRI scores and 
results of neurophysiological testing on repeat examination see Table 21.
Table 21: Correlation between neurophysiological investigations and MRI grading in 
stage II of study
Neurophysiological test r P
Central motor conducting time (CMCT) 0.25 0.21
Visual evoked potentials (VEPs) 0.28 0.19
Sural nerve conduction velocity (NCV) -0.26 0.27
r: correlation coefficient 
p:probabiiity value
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Figure 14: Plot of change in MRI grade (5MRI) against change in phe level (ôphe) between
stage 1 and II of study for the older group (14-49 years) of PKU patients
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Figure 15: Plot of change in MRI grade (ôMRI) between stages I and II of the study against
actual phe level at stage II for the older group (14-49 years) of PKU patients
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Figure 16: MRI of head in PKU patient showing improvement in scan appearance after 
reducing phe levels with dietary therapy
The arrows highlight the abnormal white matter which is more extensive on the scan on the left 
performed before phe levels were reduced.
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3.11 Serial cranial MRI on two siblings
The two siblings who returned to a strict low phe diet on a trial basis achieved phe levels In the 
desired range (<200 pmol/l) as shown in Table 22. Phe levels were reduced to < 200 pmol/l by 
days 6-7 of diet. MRI grades were 16 in sibling 1 and 13 in sibiing 2. No change was observed in 
the MRI appearances and after 3 weeks of strict dietary restriction of phe, the brothers relaxed 
their diet. These results are shown in Figure 17 and Appendix 12.
Table 22: Blood phe levels in two adults who returned to strict diet after scan on day 1
days SIBLING 1 
phe levels (pmol/l)
SIBLING 2 
phe level (pmol/l)
1 1177 1081
4 603 418
5 599 264
6 367 148
7 170 57
8 126 129
15 54 96
22 79 140
29 130 170
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Figure 17: Plot of serial MRI grades and blood phe on sibling I on returning to strict low
phe diet
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4. DISCUSSION
4.1 Introduction
In this chapter the results of the studies and their significance are discussed. The discussion is 
divided into the following topics: study design, clinical and neurophysiological findings and their 
relationship to MRI changes, relation of MRI abnormality to biochemical control and an 
interpretation of the MRI changes.
4.2 Study design
4.2.1 Study group
The patients studied all attend the PKU clinic at the Wiliink Biochemical Genetics Unit in 
Manchester. For the majority, their treatment has solely been with this clinic, occasional patients 
have entered the clinic at a later age. The patients have ‘classical’ PKU, that is phe level >1200 
pmol/l on a normal diet with a protein intake of 2g/kg (15). 78 patients were studied in total. 59 of 
these were over 14 years and had discontinued strict diet (around the age 14 years) and were 
currently taking a low protein diet (Ig/kg) or normal diet without amino acid supplement. Fifty- 
eight of this group were studied for evidence of clinical and neurophysiological abnormality as 
well as MRI scanning. The younger group (those less than 14 years) only underwent MRI 
scanning. 59 adults represents 80% of the adult group whom still attend the clinic. Some adults 
have been lost to follow-up over the years and it was considered whether these patients were 
likely to form a particular subset of patients with a milder form of PKU or a less well treated 
group with a poorer neurological outcome. Whilst this remains theoretically possible, it is unlikely 
since in terms of their diagnostic phe, IQ and duration of treatment they did not differ from the 
study group.
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The North West region of England is a large geographical area and patients studied here are 
likely to be representative of patients with PKU in UK. The one area in which this group may 
differ from the générai PKU population in UK is that dietary treatment has been continued in 
Manchester until age 14 years. This is longer than many centres in UK and Europe. If there are 
hazards after dietary discontinuation causing the development of neurologicai iiiness, then this 
group may not show problems for a number of years. The age of the group studied was 14-32 
years (except one woman aged 49 years). Other patients with neurological problems have been 
aged 18 years and been off diet for around 10 years. Hence it would be expected that this group 
is sufficiently old and large for emerging neurological difficulties to be observed.
4.2.2 Control group
The age range of participants for control neurophysiological studies was 16-40 years, average 
age 21 years. After adoiescence, nerve conduction measurements stabilise at adult values until 
around 60 years when nerve conduction slows (129) and so this is a suitable age range to use 
as control subjects.
All controls were either employed or students and are likely to be representative of an socio­
economic group i, II or III. However, there are no reports of nerve conduction being related to 
socioeconomic groups and although one could speculate that such groups will have better early 
nutrition, the results we obtained from testing these groups agree with published results in the 
literature and they were considered suitable as control data.
A control group was not considered necessary for MRI since similar abnormalities have been 
reported in PKU by several groups and MRI of brain is a standard procedure with established 
age related normal appearances.
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4.2.3 Study methods
The study was designed to recruit a large number of patients with classical PKU that could be 
considered representative of patients with PKU. Recruitment was Invitation by letter to which a 
tear-off reply was attached. Only 5 patients replied with a negative answer but some others did 
not answer or after initially indicating a willingness to participate declined to attend appointments. 
Some of these were due to travel difficulties and others were cancelled, as the patients had 
become pregnant in the interim. The method of recruitment seemed successful and a group 
accounting for 80% of the possible total was recruited.
A comprehensive neurophysiological assessment was performed which yielded important 
information. However, on repeat testing it proved difficult to get this group to return. This may 
partly have been due to the nature of the tests or it may have been the length of the 
assessment, in order to reduce the duration of the tests, the SEPs were omitted from the repeat 
assessment since they were all normal on initial testing. The outcome of the first stage coincided 
with the MRC recommendations on lifelong treatment for PKU (11). The initial study design 
included a period of observation between scans without dietary manipulation. However, after 
hearing results and MRC recommendations some patients wished to return to diet. Although this 
gave three study groups to study on repeat scanning, there was no attempt at randomisation 
and the resulting groups were of varying size. In particular, the group who opted for strict low 
phe diet consisted only of five patients.
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4.3 Clinical examination
In this study 58 patients were examined. The clinicai examination consisted of assessment of 
power, tone and reflexes of the iimbs. Rest tremor and intention tremor was noted. Cerebellar 
integrity was tested by alternating rapid hand movements and finger-nose test. Abnormalities 
were observed in 11 of the 58 patients. Brisk reflexes were present in ail these patients. 
Additionally rest tremor was observed in 6 of the 11 patients. The tremor did not worsen on 
intentional actions.
The nature of the clinical examination was chosen on the basis of previous reports of adult 
neurological deterioration in PKU (8-10,70). In these reports several individuals with PKU had 
developed definite neurological signs. Viilasana et al. (10) found spasticity of the lower limbs and 
an abnormal gait in two young adults aged 28 and 18 years. Battistini (70) noted hypotonia and 
weak abdominal reflexes in an 18 year old girl. Thompson et al. (8) have seen 7 patients with a 
combination of neurological signs; pyramidal weakness of the lower limbs and brisk reflexes, 
dystonia and cerebellar signs. Bick et al. (79) have noted normal neurological examination in a 
group of 10 adolescents. Likewise the group examined by Lou (77) were normal. However, 
Thompson et al. (71,72) in their later study of asymptomatic patients identified brisk reflexes and 
tremor in 12 of 26 patients examined. Taking these studies overall it seems that the older 
patients are the most likely to show mild neurologicai signs of tremor and brisk reflexes. The 
more specific stronger neurological abnormalities are observed in a smaller number of 
individuals. It is possible that the early treatment of some of these patients was suboptimal. 
Several of Thompson's patients had reduced intellectual function and poor growth at a young 
age. (8). However, four of the seven in the group had been diagnosed by newborn screening 
and maintained acceptable phe levels in the early years and so there is no particular reason to 
suspect that their treatment was suboptimal. Another consideration is their nutritional status. 
Serum foi ate and vitamin B12 deficiencies have been reported in PKU patients and may cause 
neurological decline (169). Folate and B12 status is documented in only one of these reports by 
Viilasana (10) and was normal. It is possible that the major neurological decline is seen in
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patients either with poor eariy treatment or iate nutritional inadequacies. The patients studied in 
my group who were well treated from birth did not show any symptomatic neurological decline. 
The patients here, although representative of PKU in the North West Region, have continued 
dietary therapy until 14 years. This factor may have some bearing on their wellbeing, as 
myeiination is known to continue at ieast throughout the first decade.
The clinical signs seen in this group and many other groups of treated PKU patients are 
considered soft neurological signs. Tremor at rest is seen in Parkinsonism and other subcortical 
dementias (165). It is also observed in anxiety states. Cerebellar tremor is usually an intention 
tremor. Brisk reflexes can be a sign of pyramidal tract involvement, In pyramidal tract 
abnormality increased tone of the muscles is usually observed. The areas of the brain that couid 
cause these signs are the motor cortex positioned in the precentral area of the frontal cortex or 
the basal ganglia. Neither of these areas are the regions of the brain especially noted as being 
abnormal on MRI scanning in PKU. It is therefore not unexpected that there is no correlation 
between clinical abnormality and the extent of white matter involvement in this group of patients. 
An alternative theory is that disturbances in neurotransmitter availability are responsible for the 
neurological abnormalities described in PKU. Deficiencies in neurotransmitter availability are 
known to occur in PKU. Dopamine, serotonin and noradrenaline availability is markedly reduced 
when phe levels are high (102-104). This form of neurological abnormality would not be 
highlighted on MRI scanning. The number of patients with neurological signs was small, 
however, in this study and any statistical significance between MRI severity and clinical 
abnormality would possibly be missed. After one year’s observation, there was little change in 
physical examination in the group. Patients with neurological abnormalities displayed similar 
signs on repeat examination. Two patients previously thought to be normal had developed brisk 
reflexes. The development of new signs did not relate to worsening of MRI appearances or to 
alteration in diet.
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4.4 Neurophysiological investigation
A comprehensive neurophysiological examination was performed in 56 adults with PKU aged 
14-49 years the majority of whom had discontinued diet at the age of 14 years. The 
neurophysiological studies were specifically chosen having reviewed the current literature in 
PKU in which it was suggested that the MRI white matter changes were a result of demyelination 
{8-10). Additionally previous neurophysiological studies had reported abnormalities in VEPs and 
NCV in PKU (10,77). Magnetic stimulation had not been previously reported at the outset of this 
study, being a relatively new technique but a report emerged during this study of CMCT in 22 
treated adolescents with PKU (78). We were particularly interested in the results of magnetic 
stimulation since the measurement can indicate delay in nerve transmissions in the pyramidal 
tract and this was the region reported by Thompson and others as being abnormal in PKU (8).
Although only 6 individuals had prolonged P I00 wave on VEP, the mean P I00 was statistically 
longer in the PKU group than in controls. This finding may represent a subtle change in VEP in 
PKU. There was no correlation between VEP latency and MR! scores, a finding corroborated by 
others. It is of interest that the main abnormality found in the neurophysiological assessment 
was in VEPs as this region of the brain was the area most commonly noted to show white matter 
pathology. Two individuals had marked prolongation of the P I00 wave with poorly formed 
waveforms. These were aged 23 and 20 years and had been on dietary therapy until the age of 
14 years. However, their biochemical control had never been good. IQ’s were 92 and 77 
respectively.
Other individuals had abnormal results on CMCT and NCV. There were no abnormal results for 
SEP. These results are not in agreement with some other published data on neurophysiology in 
PKU (78,79,146-149). This lack of agreement in neurophysiological results is probably due to 
several considerations: different patient groups ie, different severity of PKU, and different 
laboratory techniques.
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If demyelination was present in PKU it is likely that a greater degree of neurophysiological 
abnormality would have been observed. In MS, neurophysiological studies can highlight clinically 
undetectable abnormalities in nerve function although MRI is far more sensitive at detecting 
demyelinated plaques than any neurophysiological technique (132,137,163). However, when 
widespread disease is obvious on MRI then some degree of abnormality is found on 
neurophysiological testing. Also it has been observed that the combination of neurophysiological 
techniques improves the detection of areas affected by demyelination (136). In several studies, 
magnetic stimulation of the cortex has been found to be highly sensitive at detecting 
demyelination (132-134). From the relatively normal results of this assessment, it is possible to 
conclude that the MRI abnormalities are unlikely to be related to demyelination.
The lack of correlation between MRI score and any neurophysiological test is of interest. 
Perhaps the only test that seems to correlate with the distribution of MRI abnormalities is the 
VEP and other investigators have suggested that an ‘occipital syndrome’ may exist. However, 
Lou (77) and Bick (79) have not found an association between the VEP and extent of MRI 
lesions.
The functional tests performed in our study have failed to detect any major disturbance in 
neurologicai wellbeing although some minor findings of uncertain significance have been 
detected. It appears that the abnormalities resulting in the abnormal neurophysiological findings 
are unrelated to the white matter changes seen on MRI of brain.
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4.5 MR! abnormalities
4.5.1 Frequency of MRI abnormalities
MR brain scans showed abnormalities in the T2 weighted images of the white matter in 71 of the 
74 patients scanned {three patients couid not tolerate scanning due to claustrophobia). The 
three patients who had normal scans were; one girl aged 11 years who was diagnosed and 
treated at 20 days who always had good biochemical control (current phe level at time of scan 
was 100) and two other younger children had equivocal changes on scan (scoring 1 bilaterally 
i.e. the radiologist could not discern whether the scans were abnormal or not). These boys were 
aged 11, diagnosed and treated from the newborn period and their phe levels 300 and 450 p 
mol/l at time of scanning.
All the other patients showed some abnormalities on MR scanning. The abnormalities were 
similar throughout the group although they varied in degree of severity.
4.5.2 Pattern of the MRI abnormalities
The areas of the brain affected were the occipital, parietal, temporal and frontal cortices. Lesions 
in the basal ganglia were observed in two patients. No changes were observed in the cerebellum 
or brain stem.
The abnormalities consisted of a hyperintensity of the signal of the cerebral white matter on T2 
weighted images. In the majority of cases this was a diffuse homogeneous finding but in some 
patients (16 of the total group) discrete focal lesions were observed. There was a gradation in 
the severity of the abnormalities: in patients with the least change white matter abnormalities 
were seen only in the occipito-parietal region. With increasing severity white matter 
abnormalities extended into the frontal lobe and then the temporal lobe. This gradation in 
involvement of the white matter has only been suggested previously by one other investigator. 
Pearsen et al. (75) noted that the more severely affected scans involved the frontal lobes.
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However, published resuits suggest that this phenomenon was occurring in other centres. Lou et 
ai. (77) who studied a young population of adolescents with PKU report white matter change 
only in the occipitoparietai region. This study aiso found frequent EEG abnormalities in the 
occipital cortex and on this basis describe an ‘occipito-parietal syndrome’ occurring in PKU. It is 
possible that frontal lobe changes would have been observed had older patients or individuals 
with higher phe been studied.
The abnormalities were symmetrically distributed and this was reflected in the scoring. Although 
the scoring system allowed for a discrepancy between left and right by scoring each hemisphere 
separately, there was never more than one point difference between each side. The focal 
discrete lesions however, when they occurred, were asymmetrically distributed. No account of 
these was taken when scoring the scans but they were noted in a written report accompanying 
the scan.
4.5.3 Relationship of MRI scores to biochemical control
Several parameters relating to biochemical exposure to phe were examined in this study. The 
technique used was designed by Walter et al. and applied to a study of 11 Bristol schoolchildren 
with PKU (80). In that study only 4 scans were abnormal showing the characteristic 
appearances of white matter changes. There were no statistically significant associations 
between MRI severity and biochemical control but a suggestion that the children with the worst 
scans had the worst biochemical control. The study did not measure blood phe at the time of 
MRI. However, the number of patients studied was small and since they were a younger group 
they tended to have blood phe levels in the lower range. Statistical significance may have been 
reached in a larger group. We used the same computer programme in this study and found 
several factors relating to biochemical control to show statistical significance: mean blood phe 
throughout life (p=0.0043), mean blood phe in past 5 years (p=0.0025) and blood phe at the time 
of scan (p=0.0002). Stepwise multiple regression analysis showed that when phe at time of scan 
was accounted for, no other measure of biochemical control showed a significant association
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with the MRI grade. Thompson et al. (72) and Bick et al. (79) were able to establish a 
relationship between the degree of white matter change and biochemical severity. Thompson in 
particular demonstrated that recent phe levels were strongly associated with MRI severity (72). 
Their data was analysed using ordinal statistics as the results were not normally distributed. In 
our larger study the MRI did approximate to the normal distribution allowing the use of 
parametric analysis. Bick was unable to detect statistically significant associations but noticed 
the trend that MRI severity seemed to relate to recent phe exposure rather than early exposure 
(79). In my study there was no relationship between early phe exposure in the first 4 years and 
MRI score (p=0.27) nor was there a significant association between IQ and MRI score. This last 
fact is of interest as it corroborates the lack of association with MRI and eariy control since eariy 
phe control is known to be associated with final IQ.
The strong association between MRI grade and blood phe levels allows speculation on the 
cause and nature of the abnormal appearances of cerebral white matter on MRI in PKU. There 
is no information to prove a causal effect of blood phe in the production of this abnormal white 
matter appearance. However, one can speculate a causal effect based on current knowledge of 
the effects of elevated blood phe on the central nervous system and this is discussed further 
later.
Further evidence of the role of blood phe in changing white matter appearance on MRI is given 
in the second part of this study when repeat scans were performed. In the second stage of the 
study the older patients underwent scanning after a period of 3 to 12 months (median 9 months) 
and the younger group after a period of 1 year. The groups were analysed separately since the 
younger group were on diet and made no dietary alteration between scans, whereas some of the 
older patients had elected to restart some form of dietary therapy. Within the older group, some 
reduction in the extent of the white matter abnormalities was observed in those whose phe levels 
were substantially lower at repeat scan. There was a significant association between the change 
in blood phe between scans and the change in MRI score (p-0.0002). There was also a strong 
inverse correlation between blood phe at second scan and the change in MRI score (p<0.0001).
89
The scans that showed reduction in extent of changes were generally in those in whom phe 
levels were <700 pmol/l at second scan. Patients who reduced phe levels from 1800 pmoi/l to 
700-900 j.imol/1 although achieving a large 5phe tended not to show any improvement. It 
therefore seemed that the actual phe attained was more important than the degree of change in 
phe level. The correlation found in stage I of the study was still present i.e. phe at time of study 
was still significantly associated with MRI score. The reduction in severity of MRI score was a 
reflection of reduction in white matter change throughout the brain. There was a tendency to 
improve firstly in the frontal lobes and then the occipitoparietal lobes, the reverse of the way in 
which the abnormalities started. This part of the study adds weight to the theory that blood phe 
plays an important role, either directly or indirectly, in the generation of the white change seen as 
hyperintensity of the T2 images on MRI. The strength of the association of blood phe and MRI 
severity led to the question of whether blood phe could alter MRI appearances on a day to day 
or week to week basis. The further work with two adults who underwent serial scanning was 
planned to answer this question. In this small study it was observed that despite stringent 
reduction of blood phe, which was maintained for three weeks, no alteration was seen in daily or 
weekly MRI scores.
4.6 Interpretation of MRI abnormalities
4.6.1 Introduction
Although MRI is an extremely sensitive tool for investigating the brain, the images obtained are 
not specific (170). It is the best investigation available for detecting changes in the white matter 
but the interpretation of these alterations presents difficulties. Many different disorders can result 
in similar MR appearances (118). Disorders of myelin encompasses a range of problems. When 
myelin is lost from the CNS, it can be a primary or secondary defect. Primary defects are those 
where myelin is abnormally produced in a form that renders it more susceptible to breakdown or 
where an external toxin ‘attacks' the myelin sheath. Secondary myelin loss can occur when the 
axon is damaged (118). The interdependency of the axon and myelin sheath means that loss of
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myelin will ultimately lead to axonal loss and vice versa. There has been some work indicating 
axonal loss in the brains of PKU patients (171). However, the majority of current research 
suggests that PKU primarily affects myelin. Additionally the apparent reversal of MR pathology 
on re-institution of diet argues against an absence of axons with secondary non-myelination as 
the explanation of the MR findings. The interpretation of the MR abnormalities is discussed 
further in the context of a pathological effect on myelin.
4.6.2 MRI pattern in PKU compared with other white matter disorders
It is sometimes advocated that the intensity and distribution of MR changes is useful in 
suggesting the nature of the underlying neurological condition and that such ‘pattern recognition’ 
is important in interpretation of the underlying nature of the abnormalities (118). Some 
interpretation of the nature of the changes seen in PKU is discussed below in relation to the 
pattern observed.
The reason for the symmetrical distribution, the specific areas affected or the gradation in 
severity of changes remains unknown. Symmetry of MR changes suggests a systemic effect 
from raised phe but some regions of the brain seem particularly susceptible and of these some 
are affected prior to others.
In order to attempt to interpret abnormal signals it is necessary to consider their signal intensity 
and distribution. The comparison between the changes seen in PKU and and many other causes 
of hyperintense T-2 weighted signals on MRI of the brain is discussed.
Firstly, symmetry of white matter changes; in demyelinating diseases the white matter plaques 
are usually asymmetrical in their distribution (172), Symmetry of abnormal signals is seen in 
some of the metabolic dysmyelination disorders such as metachromatic leucodystrophy 
(arylsulfatase A deficiency) but with that disorder the lesions begin in the frontal lobe and 
progress towards the occipital lobe (173). In Alexander’s disease an autosomal recessive
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disorder due to aspartyl acyctase deficiency, the lesions tend to be symmetrically distributed 
(174). Symmetrical distribution seems to occur where there is a generalised toxic process. 
Demyelination seems to be more characterised by patchy involvement of the brain.
Secondly, the distribution of the PKU changes is predictable and stereotypic occurring in the 
periventricular areas of the occipital, frontal and temporal lobes. These areas of the brain are 
involved in several metabolic disorders such as Alexander’s disease and mucolipidosis (156). 
However, the intensity of the signal and the homogeneity of the abnormalities in PKU gives it a 
different appearance from these disorders.
Thirdly, the gradation of involvement according to severity of the white matter changes. This 
feature seems to be fairly typical of PKU and is not described in other de- or dysmyelinating 
disorders.
4.6.3 Are the MR changes pathological?
MRI demonstrates changes in signal intensity that correlate well with histological demonstration 
of myeiination (110). Myeiination begins during the fifth fetal month and continues throughout life 
in a predictable pattern proceeding from caudal to rostral direction (175). It proceeds rapidly up 
to 24 months of age but slows markedly after this age. It is thought that fibres in the areas 
around the lateral ventricles are amongst the slowest to myelinate. These areas are called the 
association areas of the brain and continue to myelinate throughout the first several decades of 
life (175). The late myeiination of these areas is thought to be responsible for areas of high 
signal intensity persisting in the white matter dorsal and superior to the trigones of the lateral 
ventricles on the long TR/TE images. These regions are homogeneous with indistinct margins. 
They gradually disappear usually by the end of the first decade. These images are normal 
findings and they can be differentiated from damaged brain such as periventricular leucomalacia 
(PVL) by looking for evidence of tissue loss that is seen as enlargement of the ventricles or 
atrophy at the periphery of the brain in damaged brain (117). In addition, damaged brain will
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normally show abnormal signal intensity on the first echo of a long TR sequence whereas 
unmyelinated regions do not and normal brain contains a layer of myelinated white matter 
between the trigone of the ventricle and the homogeneous high signal.
The signal intensity correlates with the degree of myeiination (158,159). This implies that MRI 
can differentiate immature white matter, myelinated white matter and gray matter. The water 
content is different in each of these and this factor probably accounts for at least some of these 
differences in signal. It has further been suggested that shortening of the T2 relaxation time in 
maturing white matter is related to protein, cholesterol or glycolipid content of the myelin sheath 
(174). The lipid proteins of myelin do not directly contribute to the MRI signal intensity. It appears 
likely that the myelin membrane is involved in the restriction of water proton motion (156,176).
It is interesting that the area of the brain most commonly affected in PKU is the white matter of 
the peritrigonal areas. In our scans there was no evidence of a strip of normal white matter as is 
seen in normal brain and there was frequently evidence of involvement in other areas of brain 
with cortical atrophy in some patients. These factors suggest that the findings in PKU represent 
pathological changes. The frequent involvement of this region may be related to the later 
completion of myeiination of these association areas, as it is possible that this younger myelin is 
more liable to the effects of hyperphe.
4.6.4 Possible effects of phe on cerebral white matter leading to production of MR signal
4.6.4.1 Introduction
It is reasonable to assume that phe either directly or indirectly is responsible for the 
abnormalities seen on MR imaging in these patients since there is a strong association with phe 
levels and the severity of the abnormalities and an association between reversal of the abnormal 
signal and reduction of blood phe levels. The aetiology of the abnormal appearance of the white
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matter in the PKU brain are now discussed in relation to the present knowledge of the 
pathological effects of raised phe on white matter.
4.6.4.2 Origin of the MR signal of white matter
The origin of the MR signal is complex but depends primarily on the proton content of tissues. 
Protons in myelin are so tightly bound that no perceptible signal is emitted from them. The main 
contributor to the T2 signal is protons of water in the white matter (156,177). Hyperintensity of 
the T2 weighted signal in the MR images results from increased water content of the white 
matter in these areas (156).
4.6.4.3 Development of the myelin sheath
Figures 18 and 19 are illustrations showing the development of the myelin sheath and 
highlighting the production of the lamellar structure. Myelin is produced by the wrapping of 
oligodendrocyte extensions around the axon. As the surfaces of the membrane become 
apposed the cytoplasm is extruded and the membranes adhere (107). The myelin sheath thus 
formed is composed of proteins, lipids and some carbohydrates. Myelin has a hydrophobic 
centre formed mainly by the lipid component and a hydrophilic coating that interacts with the 
aqueous environment. This arrangement creates a stable membrane relatively resistant to 
external toxins. There is a repeating protein-lipid-protein-lipid-protein unit. The major protein is 
proteolipid protein (PLP) which stretches across the hydrophilic and hydrophobic areas. The 
other main protein is myelin basic protein (MBP) which is located in the cytoplasmic membrane 
(107)
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Figure 18: Diagram of the oligodendrocyte extensions wrapping around the axons
Copyright 1983. Novartis. Reprinted with permission from The Ciba Collection of Medical 
Illustrations, Vol 1, Part I, Section VII, illustrated by Frank H. Netter. All rights reserved.
Development o l lha C a llu la i SKoath of Axon*
A. UnmyaOnaicd axons 
ot pailpKctal nauroat 
(sonaoty, to m ilio  motor 
Of visoarai motor) 
üeinç su Mounded by 
oyiopiavn ol t> 
rtaurilonnniii te ll
B. Uyfilwaïaü axon ol 
pori^ iM al neuron 
(sensory, eomotic motor 
cr viacaral motor)
Pal no sufrtKindao by 
a wtipping of call inomMâM of a 
nturlltinm al cell
Meanlemnuil cell
Noufilurati-.al CttI
Pn iaxonal snncr
I'C. Myallnalad.oon! p '^CNf'’flouronrbaino %  
^W rioundaiitby* . ■, % »
MjUnmyallnaieil axon*!
Hlgd^ ar&^ sMni 
nannar'ihowntiof'^i 
W llam m al.cc ll Olipoitrydrccyto
95
Figure 19: Illustrative d iagram  o f the m icroscopic structure of the m yelin  sheath show ing  
lam ellar structure
Copyright 1983. Novartis. Reprinted with permission from The Ciba Collection of Medical 
Illustrations, Vol 1, Part I, Section VII, illustrated by Frank H. Netter. All rights reserved.
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Figure 20: Illustration of the components of the myelin sheath
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4.6 4.4 Possible sites of water accumulation considered In relation to MR signal and 
effects of raised phe on white matter
Theoretically there are three possible sites of an increased water content of white matter: an 
accumulation of extracellular fluid around the myelin sheath due to loss of myelin as in MS, 
extracellular water accumulation between the lamellae of the myelin sheath (vacuolating 
myelopathy) or an increase in the intracellular water compartment of the myelin sheath. The 
arguments for each of these is discussed further below in relation to the MR pattern seen in this 
study and the known pathological effects of phe on white matter.
Raised phe levels have been observed to have several effects on brain development. The 
majority of this work relates to postmortem findings on untreated adults and on animal models 
equivalent to the untreated patient (82-85,99,104). There is also a body of work performed on 
the rat model rendered hyperphenylalaninémie at 25 days, approximately comparable with the 
treated individual who discontinues diet aged eight years (88). There are no PM studies on
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treated individuals. There is no unifying theory from these studies although certain facts emerge 
regarding the effects of elevated phe on the central nervous system.
Elevated phe levels have an effect on protein synthesis in the CNS. In PKU there is a relative 
deficiency of certain other amino acids due to competitive inhibition of phe for transport 
pathways. The deficiency of these amino acids may be a rate-limiting factor in protein synthesis. 
Low levels of both PLP and MBP, the major proteins in myelin, have been measured (99). In 
their study on rats with late-onset hyperphe, Taylor and Hommes found that myelin turnover was 
increased and that myelin was less stable (88). The patients studied in my project had continued 
treatment longer than 8 years, usually until aged around 14 years. Nevertheless, these animal 
studies suggest that phe continues to be toxic to myelin even after the rapid phase of 
myeiination is completed. Phe was thought to exert this effect by interfering with the proteins 
necessary for the synthesis of myelin. An interesting feature of this work was that the effects 
were only seen at relatively high levels of phe: a threshold seemed to exist for the interrupting 
effects of elevated phe. Another theory of phe toxicity related to its effect on ATP sulphurylase. It 
Is thought that sulphatide protects myelin and contributes to its stability (88,90,100). ATP 
sulphurylase has been shown to be inhibited by elevated phe levels in the brain thereby causing 
a reduction in levels of sulphatides. it is hypothesised that this reduction in sulphatide level may 
render myelin more vulnerable to proteolytic degradation and thereby increase myelin turnover.
Phe also has an effect on brain lipids. Early work identified reduced amounts of myelin lipids 
especially cholesterol in the brains of patients with untreated PKU (99). More recently low levels 
of essential fatty acids has been found in treated individuals with PKU (178,179). It is now 
recognised that dietary treatment in PKU reduces the levels of some polyunsaturated fatty acids 
(PUFAs) since It restricts the intake of animal fats that are rich in protein (179). As these PUFAs 
are components of structural lipids in cell membranes, they are fundamental to the normal 
development of the central nervous system. The importance of fatty acids in the diet of children 
for the normal development of the infantile cortex has been recognised (180). Specifically, levels 
of arachidonic, eicosapentaenolc and docosahexaenoic acids are reduced in circulating plasma
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lipids in treated PKU (179). Levels of linoleic and oleic acids are higher in children on a PKU diet. 
It is speculated that these derangements of fatty acids could have a detrimental effect on 
intellectual outcome in treated PKU. The degree of phe control inversely correlates with levels of 
PUFAs i.e. those individuals with low phe levels had more abnormal levels of PUFAs. Since the 
MR abnormalities in this study were more extensive in those with high phe it is unlikely that low 
PUFAs explains the MR findings. Also the MR abnormalities were more prominent in those who 
had discontinued diet whereas the low PUFA levels are a concern for those on dietary treatment. 
Although they probably do not relate to the MR images, fatty acid levels in PKU may contribute 
to the clinical problems and slightly reduced IQ’s observed in the treated PKU population.
From the work to date it is possible to speculate that raised phe in the mature PKU brain can 
cause disruption to myelin, by one or more of the explanations mentioned above and this leads 
to proteolytic breakdown and increased turnover of myelin. However, the myelin now produced 
is no longer normal since it is being continually renewed in the face of hyperphe and relative 
tyrosine deficiency. These problems could produce a poorer quality of myelin sheath. If the 
myelin was deficient predominantly in PLP, which is present on the outer layer, then it is possible 
that an increased amount of extracellular water could penetrate between the lamellae due to 
instability of the outer layer of the sheath. This would cause a picture of vacuolating myelopathy. 
If, however, there were deficiencies or alterations in ratios of lipids and/or MBP then disruption of 
the hydrophobic core or cytoplasmic membrane could ensue. This would give rise to an 
accumulation of intracellular water. If the predominant effect of raised phe was myelin loss 
similar to that observed in the demyelination of MS then water would accumulate as the 
extracellular fluid fills up the spaces left by myelin destruction. Any of these explanations could 
give similar MRI pictures. Factors which give weight to the theory that raised phe is responsible 
for myelin disruption and that is causing the abnormal MR appearances are as follows:
1) MRI is detecting some pathological process in the white matter
2) Animal model evidence is strong that phe can damage mature myelin
3) MRI changes show a strong association with phe levels
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4) Reversal of changes is observed after reducing phe; recovery of myelinogenesis is reported 
on reducing phe levels in rats with myelin damage.
5) A suggestion of a threshold effect was observed In repeat MRI studies: only after phe levels 
were below 700 pmol/l was reversal observed. A similar effect was seen in animal studies of 
myelin disruption.
However, if the MR appearances resulted from extensive demyelination, one would expect some 
abnormality in function of the nervous system that is not supported by the neurophysiological or 
clinical studies. Intracellular water usually does not contribute greatly to the MR signal since 
Intracellular water is bound to many components of the cytoplasm. It is unclear but doubtful 
whether an increase in this compartment would cause the MR findings observed in this study. 
An increase in interlamellar water seems a better explanation presently for our findings. In 
hyperphe rats the earliest pathological change observed is a disintegration of myelin with 
disruption of the myelin sheath (171). Accumulation of extracellular fluid between the lamellae 
could be a reversible feature when blood phe levels are restored to lower levels as new myelin Is 
synthesised with a more normal constituency. The time taken for reversal of changes would 
support this theory, as it would approximate to the turnover times of myelin. This explanation is 
based on an interpretation of the current knowledge but remains merely speculative.
4.7 Further work
Although this study did not identify functional neurological problems in PKU to any large degree 
it would now be important to look for more subtle evidence of neurological problems. There is 
some evidence to suggest that white matter changes as observed on cerebral MRI in PKU can 
have neuropsychological consequences (181,182). There is a growing body of evidence that 
neuropsychological abnormalities do exist in PKU particularly In executive task performance (59- 
61). These deficits have been shown to be related to current blood phe levels and 
neuropsychological performance is improved when blood phe levels are lowered. This work has 
been reported in a small group of adolescents with PKU. An Important study to follow the results
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presented in this thesis would be to perform detailed neuropsychological examination in the 
large group of patients studied in addition to MRI brain scans to seek a correlation between 
higher brain performance and MRI white matter lesions.
Although there is no suggestion of progression of abnormalities on MRI over a time period of 
one year, this study should continue by performing annual serial MRI scans in the same group of 
patients.
The explanation for the neurological decline observed In a small group of adults whose problems 
triggered this study remains unclear. It Is possible that severity of neurological outcome is 
related to underlying genetic factors, which are as yet undetermined. It is possible that there Is 
another gene implicated in the neurological phenotype of PKU in addition to phenylalanine 
hydroxylase deficiency (Dr Susan Ramus, personal communication). The adults who have 
shown specific neurological decline should be studied in more detail, Specifically it would be of 
interest to attempt to establish genotypes of that group and compare it with the many other 
adults with PKU whom remain neurologlcally well.
1 0 1
5. Conclusions
The conclusions that can be drawn from this work are as follows;
1) Cerebral white matter changes are common in adolescents and adults with PKU who were 
treated from the newborn period.
2) The white matter abnormalities are present even if still on dietary therapy,
3) The extent of white matter changes strongly relates to the blood phe levels at the time of 
scanning,
4) The white matter changes are not associated with early biochemical control,
5) The extent of white matter change is unrelated to clinical or neurophysiological abnormalities 
and
6) The abnormal Images maybe reversible when blood phe is reduced by dietary therapy.
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APPENDICES
Appendix 1 : Plot of MRI grade against central motor conducting time (CMCT)
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Appendix 2; Piot of MRI grade against central sensory conducting time (CSCT)
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Appendix 3: Plot of WIRi grade against visual evoked potential latency (VEP)
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Appendix 4: Plot of MRI grade against median nerve motor conduction velocity
Plot of MRI vs. median motor nerve conduction velocity
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Appendix 5: Plot of MRI grade against median sensory nerve conduction velocity
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Appendix 6: Plot of MRI grade against lateral popliteal nerve conduction velocity
Plot of MRI grade vs.lateral popliteal nerve conduction velocity
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Appendix 7: Plot of MRI grade against sural nerve conduction velocity
Plot of MRI grade vs. sural nerve conduction velocity
25
20
15
MR] grade
10
5 ■■
©©
© ©
@©
©
H-------------------— t -
30 35 40 45 50 55 60
sural nerve conduction velocity (ms)
_1__-----------H
65 70
109
Appendix 8: Plot of MRI grade against time blood phe was less than 120 pmol/l
Plot of MRI vs. time blood phe <120 pmol/l
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Appendix 9: Plot of MRI grade against time that blood phe greater than 1200 pmol/l
Plot of MRI grade vs. time blood phe > 1200 pmol/l
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Appendix 10: Plot of WIRl grade against average blood phe in the first four years of life
Plot of MRI grade vs. blood phe In first 4 years
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Appendix 11 : Plot of MR! grade against maximum blood phe level recorded
Plot of MRI grade vs. maximum blood phe
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Appendix 12: Plot of 5IVIRI against 6phe In younger group (aged 10-14 years) of PKU 
patients
Plot of ÔIVIRI against Ôphe in 10-14 years age group
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Appendix 13: Plot of serial MRI grades and blood phe levels in sibling 2 on returning to
strict low phe diet
sibling 2: blood phe levels and serial MRI grades on low phe
diet1200 , , 14
1000
800
blood phe 
(pmol/l) 600
400
200
1
I
0 ,
. 12
10
MRI grade
1 4 5 6 7 £
days of low phe diet
< , 1 0 
15 22 29
blood phe 
MRI grade
115
REFERENCES
1. Medical Research Council Steering Committee for the MRC/DHSS Phenylketonuria Register. 
Routine neonatal screening for phenylketonuria in the United Kingdom 1964-78. British Medical 
Journal 1981;282:1680-4.
2. Jervis GA. Studies on phenylpyruvic oligophrenia. The position of the metabolic error. J Biol 
Chem 1947;169:651-6.
3. Jervis GA. Phenylpyruvic oligophrenia deficiency of phenylalanine-oxidising system. 
Proceedings of the Society of Experimental Biology 1953;82:514-5.
4. Knox WE. Stanbury JB, Wyngaarden JB, Frederickson DS, editors.The Metabolic Basis of 
Inherited Disease. 3rd ed. New York: McGraw-Hill Book Company; 1972;Phenylketonuria. p. 
266-95.
5. Smith I, Lobascher ME, Stevenson JE, Wolff OH, Schmidt H, Grubel-Kaiser S, Bickel H. Effect 
of stopping low-phenylalanine diet on intellectual progress of children with phenylketonuria.
British Medical Journal 1978;11:723-6.
6. Cabalska B, Duszynska N, Borzymowska J, Zorska K, Koslacz-Folga A, Bozkowa K. 
Termination of dietary treatment in phenylketonuria. European Journal of Pediatrics 
1977; 126:253
7. Koch R, Azen CG, Friedman EG, Williamson ML. Preliminary report on the effects of diet 
discontinuation in PKU. J Pediatr 1982;100(6):870-5.
8. Thompson AJ. Smith I, Brenton D, You! BD, Rylance G, Davidson DC, Kendall B, Lees AJ.
116
Neurological deterioration in young adults with phenylketonuria. Lancet 1990;336(8715):602-5.
9. BIck U, Fahrendorf G, Ludolph AC, Vassallo P, Weglage J, Ullrich K. Disturbed myelination in 
patients with treated hyperphenylalaninaemia: evaluation with magnetic resonance imaging. Eur 
J Pediatr 1991;150:185-9.
10. Villasana D, Butler IJ, Williams JC, Roongta SM. Neurological deterioration in adult 
phenylketonuria. Journal of Inherited Metabolic Disease 1989;12:451-7.
11. Phenylketonuria due to phenylalanine hydroxylase deficiency: an unfolding story. Medical 
Research Council Working Party on Phenylketonuria. BMJ 1993;306:115-9.
12. Scriver CR, Rosenberg LE. Amino Acid Metabolism and Its Disorders. Philadelphia: 
Saunders; 1973;p. 39
13. Smith I. Lloyd JK, Scriver CR, editors.Genetic and Metabolic Disease in Pediatrics. London: 
Butterworths; 1985; 8, The hyperphenylalaninaemias. p. 166-210.
14. Eisensmith RC, Woo SL. Phenylketonuria and the phenylalanine hydroxylase gene. Mol Biol 
Med 1991;8:3-18.
15. Guttler F. Hyperphenylalaninemia:Diagnosis and classification of the various types of 
phenylalanine hydroxylase deficiency in childhood. Acta Paediatrica Scandinavia 
1980;Suppl.280:1-80.
16. Guttler F. Phenylketonuria: 50 years since Polling's discovery and still expanding our clinical 
and biochemical knowledge. Acta Paediatrica Scandinavia 1984;73:705-16.
17. Penrose LS, Quastel JH. Metabolic studies in phenylketonuria. Biochemical Journal
117
1937;31:266-74.
18. Bickel H. Influence of phenylalanine intake on phenylketonuria. Lancet 1953;(Oct 17):812
19. Bickel H, Gerrard J, Hickmans EM. The influence of phenylalanine intake on the chemistry 
and behaviour of a phenylketonuric child. Acta Paediatrica 1954;43:64-7.
20. Woolf LI, Griffiths R, Moncrieff A. Treatment of phenylketonuria with a diet low in 
phenylalanine. British Medical Journal 1955;i:57
21. Hanley WB, Clarke JT, Schoonheyt WE. Undiagnosed phenylketonuria in adult women: a 
hidden public health problem. Can Med Assoc J 1990;143:513-6.
22. Koch R, Levy HL, Matalon R, Rouse B, Hanley W, Azen C. The North American 
Collaborative Study of Maternal Phenylketonuria. Status report 1993. Am J Dis Child 
1993;147:1224-30.
23. Komrower GM, Sardharwalla IB, Coutts JM, Ingham D. Management of maternal 
phenylketonuria: an emerging clinical problem. Br Med J 1979;1(6175):1383-7.
24. Neonatal screening programme for phenylketonuria. BMJ 1991;303:716
25. Francis D. Diets for sick children. 4th ed. Oxford: Blackwell Scientific Publications; 1987; 9, 
Phenylketonuria, p. 224-62.
26. Clark BJ. After a positive Guthrie-what next? Dietary management for the child with 
phenylketonuria. Eur J Clin Nutr 1992;46 SuppI 1:S33-9.
27. Scriver C, Kaufman S, Woo S. Scriver C, Beaudet AL, Sly WS, Valle D, editors.The
18
Metabolic Basis of Inherited Disease, 6th ed. New York: McGraw-Hill; 1994; 15, The 
hyperphenylalaninemias. p. 495-546,
28. Tourian A, Goddard J, Puck TT. Phenylalanine hydroxylase activity in mammalian cells. 
Journal of Cellular Physiology 1969;73{2): 159-70.
29. Berry HK, Cripps R, Nicholls K, McCandless D, Harper C. Development of phenylalanine 
hydroxylase activity in guinea pig liver. Biochimica et Biophysica Acta 1971 ;261(2):315-20.
30. Ayling JE, Helfand GD, Pirson WD. Phenylalanine hydroxylase from human kidney. Enzyme 
1975,20(1 ):6-19.
31. Ayling JE, Pirson WD, al-Janabi JM, Helfand GD. Kidney phenylalanine hydroxylase from 
man and rat. Comparison with the liver enzyme. Biochemistry 1974;13(1):78-85.
32. Murthy LI, Berry HK. Phenylalanine hydroxylase activity in liver from humans and subhuman 
primates: its probable absence in kidney. Biochemical Medicine 1975;12(4):392-7.
33. Robson KJ, Chandra T, MacGillivray RT, Woo SLC. Polysome immunoprécipitation of 
phenylalanine hydroxylase mRNA from rat liver and cloning of its cDNA. Proceedings of the 
National Academy of Science USA 1982;79:4701
34. Kwok SCM, Ledley FD, DiLella AG, Robson KJH, Woo SLC. Nucleotide sequence of a full- 
length complementary DNA clone and amino acid sequence of human phenylalanine 
hydroxylase. Biochemistry 1985;24:556
35. Friedman PA, Kaufman S. Some characteristics of partially purified human liver 
phenylalanine hydroxylase. Biochim Biophys Acta 1973;293:56
119
36. Lidsky AS, Robson K, Chandra T, Barker P, Ruddle F, Woo SLC. The PKU locus in man Is 
on chromosome 12. American Journal of Human Genetics 1984;36:527
37. Lidsky AS, Law ML, Morse HG, Kao FT, Rabin M, Ruddle FH, Woo SLC. Regional mapping 
of the human phenylalanine hydroxylase gene and the phenylketonuria locus on chromosome
12. Proceedings of the National Academy of Sciences of USA 1985:82:6221
38. DiLella AG, Kwok SCM, Ledley FD, Marvit J, Woo SLC. Molecular structure and polymorphic 
map of the human phenylalanine hydroxylase gene. Biochemistry 1986;25:743
39. Morales G, Requena JM, Jimenez Ruiz A, Lopez MC, Ugarte M, Alonso C. Sequence and 
expression of the Drosophila phenylalanine hydroxylase mRNA. Gene 1990;93(2):213-9.
40. G re nett HE, Ledley FD, Reed LL, Woo SL. Full-length cDNA for rabbit tryptophan 
hydroxylase: functional domains and evolution of aromatic amino acid hydroxylases. Proc Natl 
Acad Sci U S A 1987;84{16):553Q-4.
41. Dworniczak B, Kalaydjieva L, Pankoke S, Aulehia Scholz C, Allen G, Horst J. Analysis of 
exon 7 of the human phenylalanine hydroxylase gene: a mutation hot spot? Hum Mutat 
1992;1:138-46.
42. Guldberg P, Henriksen KF, Guttler F. Molecular analysis of phenylketonuria in Denmark:
99% of the mutations detected by denaturing gradient gel electrophoresis. Genomics 
1993;17:141-6.
43. Tyfield LA, Osborn MJ, Holton JB. Molecular heterogeneity at the phenylalanine hydroxylase 
locus in the population of the South-west of England. Journal of Medical Genetics 1991;28:244-
7.
120
44. Ozguc M, Ozaip I, Coskun T, Yilmaz E, Erdem H, Ayter S. Mutation analysis in Turkish 
phenylketonuria patients. J Med Genet 1993;30:129-30.
45. John SW, Rozen R, Laframboise R, La berge C, Scriver CR. Five mutations at the PAH locus 
account for almost 90% of PKU mutations in French-Canadians from eastern Quebec. Hum 
Mutat 1992;1:72-4.
46. Wood N, Tyfield L, Bidwell J. Rapid classification of phenylketonuria genotypes by analysis 
of heteroduplexes generated by PCR-amplifiable synthetic DNA. Hum Mutat 1993;2:131-7.
47. Zschocke J, Graham CA, Carson DJ, Nevin NC. Phenylketonuria mutation analysis in 
Northern Ireland: a rapid stepwise approach. American Journal of Human Genetics 
1995;57(6):1311-7.
48. Smith I, Wolff OH. Natural history of phenylketonuria and influence of early treatment. Lancet 
1974;2(7880):540-4.
49. Dobson JC, Kushida E, Williamson M, Friedman EG. Intellectual performance of 36 
phenylketonuria patients and their non affected siblings. Pediatrics 1976;58{1):53-8,
50. Dobson JC, Williamson ML, Azen C, Koch R. Intellectual assessment of 111 four-year-old 
children with phenylketonuria. Pediatrics 1977;60(6):822-7.
51. Williamson M, Dobson JC, Koch R. Collaborative study of children treated for 
phenylketonuria: study design. Pediatrics 1977;60{6):815-21.
52. Smith I, Beasley MG, Ad es AE. Intelligence and quality of dietary treatment in 
phenylketonuria. Arch Dis Child 1990;65:472-8.
121
53. Weglage J, Funders B, Wilken B, Schubert D, Ullrich K. School performance and intellectual 
outcome in adolescents with phenylketonuria. Acta Paediatr 1993;82:582-6.
54. Smith I, Beasley MG, Ades AE. Effect on intelligence of relaxing the low phenylalanine diet in 
phenylketonuria. Arch Dis Child 1991 ;66(3):311-6.
55. Krause W, Halminski M, McDonald L, Dembure P, Salvo R, Freides D, Elsas L. Biochemical 
and neuropsychological effects of elevated plasma phenylalanine in patients with treated 
phenylketonuria. A model for the study of phenylalanine and brain function in man. J Clin Invest 
1985;75{1):40-8.
56. Pietz J, Schmidt E, Matthis P, Kobialka B, Kutscha A, de Sonneville L. EEGs in 
phenylketonuria. I: Follow-up to adulthood; II: Short-term diet-related changes in EEGs and 
cognitive function. Dev Med Child Neurol 1993;35:54-64.
57. Brunner RL, Jordan MK, Berry HK. Early-treated phenylketonuria: neuropsychologic 
consequences. Journal of Pediatrics 1983;102(6):831-5.
58. Seashore MR, Friedman E, Novelly RA, Bapat V. Loss of intellectual function in children with 
phenylketonuria after relaxation of dietary phenylalanine restriction. Pediatrics 1985;75(2):226- 
32.
59. Welsh MC, Pennington BF, Ozonoff S, Rouse B, McCabe ER. Neuropsychology of early- 
treated phenylketonuria: specific executive function deficits. Child Dev 1990;61:1697-713.
60. Brunner RL, Berch DB, Berry H. Phenylketonuria and complex spatial visualization: an 
analysis of information processing. Dev Med Child Neurol 1987;29(4):460-8.
61. Diamond A. Ciaramitaro V, Donner E, Djali S, Robinson MB. An animal model of early-
122
treated PKU. J Neurosci 1994;14{5):3072-82.
62. Smith I, Beasley MG, Wolff OH, Ades AE. Behaviour disturbance in 8-year-old children with 
early treated phenylketonuria. Report from the MRC/DHSS Phenylketonuria Register. Journal of 
Pediatrics 1988;112(3):403-8.
63. Holtzman NA, Kronmal RA, van Doorninck W, Azen C, Koch R. Effect of age at loss of 
dietary control on intellectual performance and behaviour of children with phenylketonuria. N 
Engl J Med 1986;314(10);593-8.
64. Koff E, Kammerer B, Boyle P, Pueschel SM. Intelligence and phenylketonuria: effects of diet 
termination. J Pediatr 1979;94(4):534-7.
65. Waisbren S E, Schnell R, R., Levy H, L. Diet termination in children with phenylketonuria: A 
review of psychological assessment used to determine outcome. J Inherited Metab Dis 
1980;3:149
66. Beasley MG, Costello PM, Smith I. Outcome of treatment in young adults with 
phenylketonuria detected by routine neonatal screening between 1964 and 1971. Quarterly 
Journal of Medicine 1994;87:155-60.
67. Fisch RO, Chang PN, We is berg S, Guldberg P, Guttler F, Tsai MY. Phenylketonuric patients 
decades after diet. Journal of Inherited Metabolic Disease 1995;18(3):347-53.
68. Ris MD, Williams SE, Hunt MM, Berry HK, Leslie N. Early-treated phenylketonuria: adult 
neuropsychologic outcome. Journal of Pediatrics 1994;124{3):388-92.
69. Naughten ER, Kiely B, Murphy D. Phenylketonuria: outcome and problems in a 'diet-for-life' 
clinic. Eur J Pediatr 1987;146{Suppl 1):23-4.
123
70. Battistini S, de Stefa no N, Parlant! S, Federico A. Unexpected white matter changes in an 
early treated PKU case and improvement after dietary treatment. Funct Neurol 1991;6:177-80.
71. Thompson AJ, Smith I, Kendall BE, Youl BD, Brenton D. Magnetic resonance imaging 
changes in early treated patients with phenylketonuria. Lancet 1991;337:1224
72. Thompson AJ, Tillotson S, Smith I, Kendall B, Moore SG, Brenton DP. Brain MRI changes in 
phenylketonuria. Associations with dietary status. Brain 1993;116:811-21.
73. Shaw DW, Maravilla KR, Weinberger E, Garretson J, Trahms CM, Scott CR. MR Imaging of 
phenylketonuria. AJNR Am J Neuroradiol 1991;12:403-6.
74. Shaw DW, Weinberger E, Maravilla KR. Cranial MR in phenylketonuria. J Comput Assist 
Tomogr 1990;14:458-60.
75. Pearsen KD, Gean Marton AD, Levy HL, Davis KR. Phenylketonuria; MR imaging of the 
brain with clinical correlation. Radiology 1990;177:437-40.
76. Toma P, Oddone M, Lucigrai G, Cerone R, Romano C, Pelizza A. Phenylketonuria (PKU): 
Brain magnetic resonance (MR) findings. Neuropediatrics 1991;22:174
77. Lou HC, Toft PB, Andresen J, Mikkelsen 1, Olsen B, Guttler F, Wieslander S, Henriksen O. 
An occipito-temporal syndrome in adolescents with optimally controlled hyperphenylalaninaemia. 
J Inherit Metab Dis 1992;15:687-95.
78. Ludolph AC, Ullrich K, Nedjat S, Masur H, Bick U. Neurological outcome in 22 treated 
adolescents with hyperphenylalaninemia. A clinical and electrophysiological study. Acta Neurol 
Scand 1992;85:243-8.
124
79. Bick U, Ullrich K, Stober U, Moller H, Schuierer G, Ludolph AC, Oberwittler C, Weglage J, 
Wendel U. White matter abnormalities in patients with treated hyperphenylalaninaemia; 
magnetic resonance relaxometry and proton spectroscopy findings. European Journal of 
Pediatrics 1993;152(12):1012-20.
80. Walter JH, Tyfield LA, Holton JB, Johnson C. Biochemical control, genetic analysis and 
magnetic resonance imaging in patients with phenylketonuria. European Journal of Pediatrics 
1993;152:822-7.
81. Leuzzi V, Gualdi GF, Fabbrizi F, Trasimena G, Di Biasi C, Antonozzi I. Neuroradiological 
(MRI) abnormalities in phenylketonuric subjects: clinical and biochemical correlations. 
Neuropediatrics 1993;24:302-6.
82. Shah SN, Peterson NA, McKean CM. Lipid composition of human cerebral white matter and 
myelin in phenylketonuria. Journal of Neurochemistry 1972;19:2369-76.
83. Malamud N. Neuropathology of phenylketonuria. Journal of Neuropathology 1966;25:254-68.
84. Alvord EC, Stevenson LD. Vogel FS, Engle RL. Neuropathological findings in phenylpyruvic 
oligophrenia (phenylketonuria). Journal of Neuropathology 1950;9:298-310.
85. Poser CM, van Bogaert L. Neuropathologic observations in phenylketonuria. Brain 
1959;82:1-9.
86. Reynolds R, Burri R, Herschkowitz N. Retarded development of neurons and oligodendroglia 
in rat forebrain produced by hyperphenylalaninemia results in permanent deficits in myelin 
despite long recovery periods. Exp Neurol 1993;124:357-67.
125
87. Reynolds R, Burri R. Mahal S, Herschkowitz N. Disturbed myelinogenesis and recovery in 
hyperphenylalaninemia in rats: an immunohistochemical study. Exp Neurol 1992; 115:347-67.
88. Taylor EH, Hommes FA. Effect of experimental hyperphenylalaninemia on myelin 
metabolism at later stages of brain development. Int J Neurosci 1983;20(3-4):217-27.
89. Taylor EH, Hommes FA, Stewart DE. Effect of experimental hyperphenylalaninemia on 
biogenic amine synthesis at later stages of brain development. Biochem Med 1983;29(3):307- 
17.
90. Hommes FA. On the mechanism of permanent brain dysfunction in hyperphenylalaninemia. 
Biochem Med Metab Biol 1991;46:277-87.
91. McDonald JD, Bode VC, Dove WF, Shedlovsky A. The use of N-ethyl-N-nitrosourea to 
produce mouse models for human phenylketonuria and hyperphenylalaninemia. Prog Clin Biol 
Res 1990;340C:407-13.
92. Shedlovsky A, McDonald JD, Symula D, Dove WF. Mouse models of human 
phenylketonuria. Genetics 1993;134:1205-10.
93. McDonald JD, Bode VC, Dove WF, Shedlovsky A. Pahhph-5: a mouse mutant deficient in 
phenylalanine hydroxylase. Proc Natl Acad Sci U S A  1990;87:1965-7.
94. Neame KE. Phenylalanine as inhibitor of transport of amino acids in brain. Nature 
1961;192:173-4.
95. Bessman SP, Choi H, Tomaszewski L. The justification theory: the effect of tyrosine 
deficiency on tubulin synthesis in the brain. Prog Clin Biol Res 1982;79:187-92.
126
96. Scriver CR, Cole DE, Houghton SA, Levy HL, Grenier A, Laberge C. Cord-blood tyrosine 
levels in the full-term phenylketonuric fetus and the "justification hypothesis". Proc Natl Acad Sci 
U S A  1980;77(10):6175-8.
97. Batshaw ML, Valle D, Bessman SP. Unsuccessful treatment of phenylketonuria with 
tyrosine. J Pediatr 1981 ;99(1):159-60.
98. Burri R, Steffen C, StiegerS, Brodbeck U, Colombo JP, Herschkowitz N. Reduced 
myelinogenesis and recovery in hyperphenylalaninémie rats. Correlation between brain 
phenylalanine levels, characteristic brain enzymes for myelination, and brain development. Mol 
Chem Neuropatho! 1990;13:57-69.
99. Prensky AL, Carr S, Moser HW. Development of myelin in inherited disorders of amino acid 
metabolism. A biochemical investigation. Archives of Neurology 1968;19:552-8.
100. Matsuo K, Hommes F. Regional distribution of the phenylalanine-sensitive ATP- 
sulphurylase in brain. J Inherit Metab Dis 1987;10(1):62-5.
101. Lou HC, Lykkelund C, Gerdes AM, Udesen H, Bruhn P. Increased vigilance and dopamine 
synthesis by large doses of tyrosine or phenylalanine restriction in phenylketonuria. Acta 
Paediatr Scand 1987;76(4):560-5.
102. Curtius HC, Niederwieser A, Viscontini M, Leimbacher W, Wegmann H, Blehova B, Rey F, 
Schaub J, Schmidt H. Serotonin and dopamine synthesis in phenylketonuria. Adv Exp Med Biol 
1981;133:277-91.
103. Butler IJ, O'Flynn ME, Seifert WE, Jr., Howell RR. Neurotransmitter defects and treatment 
of disorders of hyperphenylalaninemia. J Pediatr 1981;98(5):729-33.
127
104. McKean CM. The effects of high phenylalanine concentration on serotonin and 
catecholamine metabolism in the human brain. Brain Research 1972:47:469
105. Guttler F, Lou H. Dietary problems of phenylketonuria: effect on CNS transmitters and their 
possible role in behaviour and neuropsychological function. J Inherit Metab Dis 1986;9 SuppI 
2:169-77.
106. Hildebrand C, Remahl S, Persson H, Bjartmar C. Myelinated nerve fibres in the CNS. Prog 
Neurobiol 1993;40(3):319-84.
107. Deber CM, Reynolds SJ. Central nervous system myelin: structure, function, and 
pathology. Clin Biochem 1991 ;24(2):113-34.
108. Martinez M. Evrard P, Minkowski A, editors.Developmental Neurobiology. New York: 
Vevey/Raven Press; 1989;Biochemical changes during early myelination of the human brain.
109. Singer HS, Chiu AY. Meiri KF, Morell P, Nelson PG, Tennekoon G. Advances in 
understanding the development of the nervous system [editorial]. Curr Opin Neurol 
1994;7{2): 153-9.
110. Barkovich AJ, Kjos BO, Jackson DE, Jr., Norman D. Normal maturation of the neonatal and 
infant brain: MR imaging at 1.5 T. Radiology 1988; 166(1 Pt 1): 173-80.
111. Ballesteros MC, Hansen PE, Soila K. MR imaging of the developing human brain. Part 2. 
Postnatal development. Radiographies 1993; 13(3):611-22.
112. van der Knaap MS, Valk J, Bakker CJ, Schooneveld M, Faber JA. Willemse J, Gooskens 
RH. Myelination as an expression of the functional maturity of the brain. Developmental 
Medicine & Child Neurology 1991;33(10):849-57.
128
113. Dietrich RB. Magnetic resonance imaging of normal brain maturation. Seminars in 
Perinatology 1990;14(3):201-11.
114. Benes FM, Turtle M, Khan Y, Farol P. Myelination of a key relay zone in the hippocampal 
formation occurs in the human brain during childhood, adolescence, and adulthood. Archives of 
General Psychiatry 1994;51(6):477-84.
115. Hayakawa K, Konishi Y, Kuriyama M, Konishi K, Matsuda T. Normal brain maturation in 
MRI. Eur J Radiol 1991;12(3);208-15.
116. Baierl P, Forster C, Fendel H, Naegele M, Fink U, Kenn W. Magnetic resonance imaging of 
normal and pathological white matter maturation [see comments]. Pediatric Radiology
1988; 18(3): 183-9.
117. Barkovich AJ. Magnetic Resonance imaging of the Brain and Spine. New York: Raven 
Press; 1991; 8, Brain development: normal and abnormal, p. 129-73.
118. van der Knapp MS. Myelination and myelin disorders a magnetic resonance study in 
infants, children, and young adults. Dordrecht: ICG Printing; 1991;
119. Coetzee T, Fujita N, Dupree J, Shi R, Blight A, Suzuki K, Popko B. Myelination in the 
absence of galactocerebroside and sulfatide: normal structure with abnormal function and 
regional instability. Cell 1996;86(2):209-19.
120. Lajtha A, Toth J, Fujimoto K, Agrawal HC. Turnover of myelin proteins in mouse brain in 
vivo. Biochemical Journal 1977;164(2):323-9.
121. Hirano A. Review of the morphological aspects of remyelination. [Review]. Developmental
129
Neuroscience 1989;11(2):112-7.
122. Haliiday AM. Visual evoked potentials In demyellnating disease. Advances In Neurology 
1981:31:201-15:201-15.
123. Halllday AM. Sensory evoked potentials. British Journal of Hospital Medicine 
1989;41(1):50-9.
124. Modes R, Larrabee MG, German W. The human electromyogram in response to nerve 
stimulation and the conduction velocity of motor axons. Archives of Neurological Psychiatry 
1948:60:340
125. Lambert EH. Diagnostic value of electrical stimulation of motor nerves, 
Electroencephalography and Clinical Neurophysiology 1962:9(suppl 2)
126. Simpson JA. Fact and fallacy In measurement of conduction velocity In motor nerves. 
Journal of Neurology, Neurosurgery and Psychiatry 1964:27:381
127. Mayer RF. Nerve conduction studies In man. Neurology 1963:13:1021
128. deJesus PV, Hausmanowa-Petrusewicz 1, Barchi RL, The effect of cold on nerve 
conduction of human slow and fast nerve fibers. Neurology 1973:23:1182
129. Wagman IH, Lesse H. Maximum conduction velocities of motor fibers of ulnar nerve In 
human subjects of various ages and sizes. Journal of Neurophysiology 1952:15:235
130. Geddes LA. Chokroverty S, editors.Magnetic stimulation In clinical neurophysiology. 
Boston: Butterworths: 1990: 2, The history of stimulation with eddy currents due to time-varying 
magnetic fields, p. 5-11.
130
131. Barker AT, Freeston IL, Jalinous R, Jarratt JA. Clinical evaluation of conduction time 
measurements in central motor pathways using magnetic stimulation of the human brain. Lancet 
1986:1:1325-6.
132. Hess CW, Mills KR, Murray NM. Measurement of central motor conduction in multiple 
sclerosis by magnetic brain stimulation. Lancet 1986:2(8503):355-8.
133. Ingram DA, Thompson AJ, Swash M. Central motor conduction In multiple sclerosis: 
evaluation of abnormalities revealed by transcutaneous magnetic stimulation of the brain. J 
Neurol Neurosurg Psychiatry 1988:51 (4):487-94.
134. Berardelli A, Inghilleri M, Cruccu G, Fornarelli M, Accornero N, Manfredi M. Stimulation of 
motor tracts in multiple sclerosis. J Neurol Neurosurg Psychiatry 1988:51 (5):677-83.
135. Epstein CM, Fernandez Beer E, Weissman JD, Matsuura S. Cervical magnetic stimulation: 
the role of the neural foramen. Neurology 1991:41(5):677-80.
136. Jarratt JA, Barker AT, Freeston IL, eta l. Chokroverty S, editors.Magnetic stimulation in 
clinical neurophysiology. Boston: Butterworths: 1990: 14, Magnetic stimulation of the human 
nervous system: clinical applications, p. 185-203.
137. Mayr N, Baumgartner C, Zeitlhofer J, Deecke L. The sensitivity of transcranial cortical 
magnetic stimulation in detecting pyramidal tract lesions in clinically definite multiple sclerosis. 
Neurology 1991:41{4):566-9.
138. Aminoff MJ, Goodin DS. Visual evoked potentials. [Review], Journal of Clinical 
Neurophysiology 1994:11 (5):493-9.
131
139. Jeffreys DA. Human visual evoked potentials (VEPs) to pattern stimuli. Brain Research 
1971;31(2):369-70.
140. Jeffreys DA. Cortical source locations of pattern-related visual evoked potentials recorded 
from the human scalp. Nature 1971;229(5285):502-4.
141. Ellingson RJ, Lathrop GH, Danahy T, Nelson B. Variability of visual evoked potentials in 
human infants and adults. Electroencephalography & Clinical Neurophysiology 1973;34{2):113- 
24.
142. Haliiday AM. Changes in the form of cerebral evoked responses in man associated \A/ith 
various lesions of the nervous system. Electroencephalography and Clinical Neurophysiology 
1967;Suppl 25:178
143. Dawson GD. A summation technique for the detection of small evoked potentials. 
Electroencephalography and Clinical Neurophysiology 1954;6:65-84.
144. Schafer EWP, McKean CM. Evidence that monoamines influence human evoked 
potentials. Brain Research 1975;99:49-58.
145. Creel D, Buehler BA. Pattern evoked potentials in phenylketonuria.
Electroencephalography and Clinical Neurophysiology 1982;53:220-3.
146. Pueschel SM, Fogelson-Doyle L, Kammerer B, Matsumiya Y. Neurophysiological, 
psychological and nutritional investigations during discontinuation of the phenylalanine-restricted 
diet in children with classical phenylketonuria. Journal of Mental Deficiency Research 
1983;27:61-7.
147. Korinthenberg R, Ullrich K, Fullenkemper F. Evoked potentials and electroencephalography
132
in adolescents with phenylketonuria. Neuropediatrics 1988;19:175-8.
148. Landi A, Ducati A, Viliani R, Longhi R, Riva E, Rodocanachi C, Giovannini M. Pattern- 
reversal visual evoked potentials in phenylketonuric children. Childs Nervous System 
1987;3(5):278-81.
149. Jones SJ, Turano G, Kriss A. Shawkat F, Kendall B, Thompson AJ. Visual evoked 
potentials in phenylketonuria: association with brain MRI, dietary state, and IQ. Journal of 
Neurology, Neurosurgery & Psychiatry 1995;59(3):260~5.
150. Pietz J, Lutcke A, Sontheimer D, Benninger C, Pietz B, Batzler U, Heusser A. EEG 
development in early treated PKU patients from birth to 6 years of age. Eur J Pediatr 1990; 149 
SuppI 1:S28-33.
151. Epstein CM, Trotter JF, Averbook A, Freeman S, Kutner MH, Elsas LJ. EEG mean 
frequencies are sensitive indices of phenylalanine effects on normal brain. 
Electroencephalography and Clinical Neurophysiology 1989;72:133-9.
152. De Giorgis GF. Antonozzi I, Del Gastello PG, Rosano M, Loizzo A. EEG as a possible 
prognostic tool in phenylketonuria. Electroencephalography and Clinical Neurophysiology 
1983;55:60-8.
153. Krause W, Epstein C, Averbook A, Dembure P, Elsas L. Phenylalanine alters the mean 
power frequency of electroencephalograms and plasma L-DOPA in treated patients with 
phenylketonuria. Pediatric Research 1986;20:1112-6.
154. Doyle F FI, Gore JC, Pennock JM, Bydder GM, Orr JS, Steiner RE, Young IR, Burl M, Clow 
H, Gilderdale DJ, etal. Imaging of the brain by nuclear magnetic resonance. Lancet 
1981;2{8237):53-7.
133
155. Young IR, Hall AS, Pallls CA, Legg NJ, Bydder GM, Steiner RE. Nuclear magnetic 
resonance imaging of the brain in multiple sclerosis. Lancet 1981 ;2(8255):1063-6.
156. Brant-Zawadski M. MR imaging of the brain. Radiology 1988;166:1-10.
157. Earnest F, 4th, Baker HL, Jr., Kispert DB, Laws ER, Jr. Magnetic resonance imaging vs. 
computed tomography: advantages and disadvantages. Clin Neurosurg 1985;32:540-73.
158. Jernigan TL, Trauner DA, Hesselink JR, Tallal PA. Maturation of human cerebrum 
observed in vivo during adolescence. Brain 1991;114(Pt 5):2037-49.
159. Autti T, Raiainko R. Vanhanen SL, Kallio M, Santavuori P. MRI of the normal brain from 
early childhood to middle age.I. Appearances on T2- and proton density-weighted images and 
occurrence of incidental high-signal foci. Neuroradiology 1994;36:644-8.
160. Autti T, Raininko R, Vanhanen SL, Kallio M, Santavuori P. MRI of the normal brain from 
early childhood to middle age. II. Age dependence of signal intensity changes on T2-weighted 
images. Neuroradiology 1994;36:649-51.
161. Truyen L, Gheuens J, Van de Vyver FL, Parizel PM, Peersman GV, Martin JJ. Improved 
correlation of magnetic resonance imaging (MRI) with clinical status in multiple sclerosis (MS) by 
use of an extensive standardized imaging-protocol. J Neurol Sci 1990;96(2~3): 173-82.
162. Scaioli V, Rumi V, Cimino C, Angelini L. Childhood multiple sclerosis (MS): multimodal 
evoked potentials (EP) and magnetic resonance imaging (MRI) comparative study. 
Neuropediatrics 1991 ;22(1 ): 15-23.
163. Miller DH, Newton MR, van der Poel JC, du Boulay EP, Haliiday AM, Kendall BE, Johnson
134
G, MacManus DG, Moseley IF, McDonald Wl. Magnetic resonance imaging of the optic nerve in 
optic neuritis. Neurology 1988;38(2): 175-9.
164. Hess CW, Mills KR, Murray NM, SchrieferTN. Magnetic brain stimulation; central motor 
conduction studies in multiple sclerosis. Ann Neurol 1987;22(6):744-52.
165. McLeod J. McLeod J, editors.Clinical Examination. Fifth ed. Edinburgh: Churchill 
Livingstone: 1979; 8, The Nervous System.
166. Fuggle PW, Tokar S, Grant DB, Smith I. Rising IQ scores in British children: recent 
evidence. Journal of Child Psychology & Psychiatry & Allied Disciplines 1992;33(7):1241-7.
167. Smith I, Beasley M. Intelligence and behaviour in children with early treated 
phenylketonuria. A report from the MRC/DHSS phenylketonuria register. European Journal of 
Clinical Nutrition 1989;43 SuppI 1:1-5:1-5.
168. Schady W, Dick JP, Sheard A, Crampton S. Central motor conduction studies in hereditary 
spastic paraplegia. J Neurol Neurosurg Psychiatry 1991;54(9):775-9.
169. Hanley WB, Feigenbaum A, Clarke JT, Schoonheyt W, Austin V. Vitamin B12 deficiency in 
adolescents and young adults with phenylketonuria [letter]. Lancet 1993;342(8877):997
170. Edwards MK, Bonnin JM. Magnetic Resonance Imaging of the Brain and Spine. New York: 
Raven Press; 1991; 15, White matter diseases, p. 467-500.
171. Huether G, Neuhoff V, Kaus R. Brain development in experimental 
hyperphenylalaninaemia: disturbed proliferation and reduced cell numbers in the cerebellum. 
Neuropediatrics 1983;14(1):12-9.
135
172. Ormerod IE, Miller DH, McDonald Wl, du Boulay EP, Rudge P, Kendall BE, Moseley IF, 
Johnson G, Tofts PS, Haliiday AM. The role of NMR imaging in the assessment of multiple 
sclerosis and isolated neurological lesions. A quantitative study. Brain 1987;110(Pt 6):1579-616.
173. Cassedy KJ, Edwards MK. Metabolic and degenerative diseases of childhood. Top Magn 
Reson Imaging 1993;5(2):73-95.
174. Grodd W, Krageloh Mann I, Klose U, Sauter R. Metabolic and destructive brain disorders in 
children: findings with localized proton MR spectroscopy. Radiology 1991 ;181(1): 173-81.
175. Yakovlev PI, Lecours AR. Regional developmental of the brain in early life. Philadelphia: 
Blackwell Scientific; 1967;The myelogenic cycles of regional maturation of the brain, p. 3-69.
176. Barkovich AJ, Lyon G, Evrard P. Formation, maturation, and disorders of white matter. 
AJNR Am J Neuroradiol 1992;13(2):447-61.
177. Girard N, Raybaud C, du Lac P. MRI study of brain myelination. J Neuroradiol 
1991;18(4):291-307.
178. Sanjurjo P, Perteagudo L, Rodriguez Soriano J, Vilaseca A, Campistol J. Polyunsaturated 
fatty acid status in patients with phenylketonuria. J Inherit Metab Dis 1994;17(6):704-9.
179. Giovannini M, Biasucci G, Agostoni C, Luotti D, Riva E. Lipid status and fatty acid 
metabolism in phenylketonuria. J Inherit Metab Dis 1995;18(3):265-72.
180. Farquharson J, Jamieson EC, Abbasi KA, Patrick WJ, Logan RW, Cockburn F. Effect of 
diet on the fatty acid composition of the major phospholipids of infant cerebral cortex, Arch Dis 
Child 1995;72(3):198-203.
136
181. Shapiro EG, Lipton ME, Krivit W. White matter dysfunction and its neuropsychological 
correlates; a longitudinal study of a case of metachromatic leukodystrophy treated with bone 
marrow transplant. J Clin Exp Neuropsychol 1992; 14(4):610-24.
182. Leuchter AF, Dunkin JJ, Lufkin RB, Anzai Y, Cook lA, Newton TF. Effect of white matter 
disease on functional connections in the aging brain. Journal of Neurology, Neurosurgery and 
Psychiatry 1994;57:1347-54.
^ L ‘\SGOW IW! ' '^ smr I J
137
